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ABSTRACT
Two studies were performed to determine the effects of resistant starch (RS) on body
weight and fat. A 2x2 factorial design was used in both studies, and results were considered
significant when p<0.05 for both studies. The first study examined the effects of RS in a high fat
diet (44.8% of energy) on weight, fat, peptide-YY (PYY) levels, and cecal pH in male SpragueDawley rats. Rats were fed a low fat energy control diet for one week prior to diet treatment. On
week two, rats were blocked by weight and fed one of the following diets for 12 weeks (n=10):
low fat, energy control (LFEC); LF resistant starch (LFRS); high fat, energy control (HFEC); or
high fat resistant starch (HFRS). RS did not lower weight or fat with either the HF or LF diets.
RS consumption resulted in greater full and empty cecal weights, and a lower pH for the LFRS
diet. This data indicate fermentation, even though weight and fat loss did not occur. This is
contrary to previous reports with RS, which has been shown to decrease body fat compared to
controls. The second study examined the effects of RS on the weight, fat, PYY levels, and
glucagon-like peptide-1 (GLP-1) levels in female Sprague-Dawley rats. Ovariectomized (OVX)
rats were used to represent rats prone to gaining weight, and sham rats represented normal rats.
Rats were assigned to one of four groups (n=10): OVEC, OVRS, SHEC, or SHRS. Rats were fed
the EC diet for 6 weeks prior to diet treatment to gain weight after surgery, and then blocked by
weight and fat into diet treatment groups, and spent 13 weeks on treatment diets. Energy intake,
total gastrointestinal weight, large intestine/cecum weight, and small intestine weight were all
higher in RS fed rats relative to EC fed rats. Mesenteric, ovarian, perirenal, retroperitoneal, and
total fat pads were lower in RS rats relative to EC rats. Although RS was not effective in
lowering body weight or body fat in the first study, the data indicates that resistant starch may
lower

body

weight

and

fat
viii

in

postmenopausal

women.

CHAPTER 1
INTRODUCTION
Overweight and obesity continue to be a growing problem in the United States among
children, adolescents, and adults and across all ethnicities. According to Ogden et al, in 20032004, the prevalence of obesity among men and women were 31.1% and 33.2%, respectively.
Data for female children and adolescents show an increase in the prevalence of overweight from
13.8% in 1999-2000 to 16% in 2003-2004, while male children and adolescents increased from
14% to 18.2% in the prevalence for overweight in these same years. According to the data by
Ogden et al, approximately 30% of non-Hispanic white adults were classified as obese in 20032004, as well as 45% of non-Hispanic black adults and 36.8% of Mexican Americans (Ogden et
al., 2006). With this growing prevalence among a variety of ages, races, and genders,
overweight, defined as a body mass index (BMI) of 25-29.9, and obesity, defined as a BMI of ≥
30, are major public health concerns in the United States and many other countries across the
globe (Grudy, 2004; Ogden et al., 2006). This concern is due to its association with other lifethreatening medical conditions such as cardiovascular disease (Grudy, 2004), diabetes (Mokdad,
2001) hypertension (Montani, Antic, Yang, & Dulloo, 2002), and a variety of cancers (Wellman
& Freidberg, 2002). Because of these comorbidities, it is evident that prevention and treatment of
overweight and obesity are of extreme importance.
Obesity can be attributed to a plethora of factors, and may also be the result of a multifactorial environment. In the westernized society, however, overweight and obesity are often
credited to the consumption of a high fat diet because of its relatively high energy value (Roy et
al., 2003). Diets high in fat are generally considered more palatable and flavorable (Seidell,
1

1998), which can lead to even more consumption. Another population affected by an increase in
body fat is postmenopausal women. Upon cessation of menstruation, the hormone estrogen is no
longer produced and released (Danilovich et al., 2000). Estrogen has been well established as a
factor in energy metabolism, and its absence is associated with fat accumulation (Shimizu et al.,
1997). The postmenopausal woman has 20% more body fat (Ley, Lees, & Stevenson, 1992), and
puts her at risk for cardiovascular and diabetic complications (Lean, Han, & Seidell, 1998). Diet
therapy is among the possible treatment options for both of these causes of weight gain and has
the potential to reduce body fat.
Of the selection of foods targeted for therapeutic use in the treatment and management of
obesity, starches and dietary fiber have received much attention or their effects on food intake
and weight status. Studies have reported that these foods do so by a variety of mechanisms, such
as by promoting satiety sooner, by slowing gastric emptying (Stephen, 1991; Anderson, Smith,
& Gustafson, 1994), by diluting energy of the diet (Topping & Clifton, 2001), and by decreasing
the absorption of fatty acids (Van Horn, 1997). Resistant starch, in particular, may be a useful
tool in combating obesity. Dietary resistant starches are defined as non-digestible fibers that
resist, to varying degrees, amylase digestion in the small intestine and are fermented to shortchain fatty acids (SCFA) by microflora in the large intestine (Higgins, 2004). Resistant starch
has many similar effects as dietary fiber and may also help in reducing body weight and body fat,
as well as protecting against colorectal cancer (Topping & Clifton, 2001) and reducing
postprandial glycemia and insulinemia (Raben et al., 1994). The production of SCFAs, mainly
acetate, propionate, and butyrate (Topping & Clifton, 2001), when resistant starch is fermented,
reduces the pH of the gut and may have an important role in reducing body weight and fat (Silvi,
Rumney, Cresci, & Rowland 1999).
2

The mechanism by which resistant starch may aid in weight loss is through increasing the
gene expression and production of peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) in
the gut via the production of the SCFAs (Keenan et al., 2006a). Both of these gastrointestinal
peptides have been shown to reduce food intake (Batterham et al., 2003; Hillebrand, de Wied, &
Adan, 2002). If this is the means by which resistant starch reduces food intake and lowers body
weight and fat, animals fed diets containing resistant starch will have higher circulating blood
levels of PYY and GLP-1. Resistant starch is also known to dilute the energy density of the diet
in the same way as fermentable fibers, although not as much as non-fermentable fibers.
However, resistant starch as a fermentable fiber fed to animals showed increased gene
transcription for PYY and proglucagon in cecal epithelial cells, increased large intestine gene
transcription for PYY and proglucagon, and greater plasma levels of PYY and GLP-1 compared
to non-fermentable fibers. Acting in the same way as a fermentable fiber, resistant starch has also
been shown to help reduce abdominal fat in rats (Keenan et al., 2006a). For these reasons,
resistant starch is implicated as a promising tool in the management and treatment of obesity.
Study 1 will determine the effects of resistant starch on rats fed high fat (HF) and low fat
(LF) diets. Study 2 will determine the effects of resistant starch on the weight and body fat of
bilaterally ovariectomized (OVX) rats versus sham-operated rats (SH). OVX female rats will be
used because they are known to gain body fat due to the lack of estrogen, and are a good model
to test the hypothesis that resistant starch reduces body fat using an endocrine model of obesity
(Ainslie, 2001).
OBJECTIVES
The objectives of Study 1 are to determine the effects of resistant starch on weight, body
fat, and, cecal weights, and gut signaling of rats on a high fat diet. The objectives of Study 2 are
3

to determine the effects of resistant starch on the weight, body fat, and gut signaling of OVX rats
and SH rats, and also to determine the effects of resistant starch on cecal weights as an indicator
of fermentation.
HYPOTHESIS
It is hypothesized that obesity-induced animals fed a diet containing resistant starch will
have lower body weight, lower percentage of body fat, lower abdominal fat, greater
fermentation, and greater plasma levels of PYY and GLP-1 than those fed a diet without resistant
starch.
ASSUMPTIONS
•

It is assumed that the rat model will have a digestive physiology and a habitual diet with
a composition as close as possible to humans.

•

It is assumed that abdominal fat will correlate to total body fat.

•

It is assumed that all measurements from the studies will be taken and recorded correctly.

•

It is assumed that animal blood and tissue collections are representative of human
subjects.

LIMITATIONS
•

Not all of the same measurements were taken for both studies.

•

NMR was deemed not effective as a measure of total body fat.

•

Although the rat model has a similar digestive physiology to that of humans, the results
from this study may not directly apply to humans.

4

CHAPTER 2
REVIEW OF LITERATURE
DIETARY FIBER
Dietary fiber is considered a group of non-starch polysaccharides and lignins of plant
origin (Liu et al., 2002; Ajani, Ford, & Mokdad, 2004) that are resistant to digestion by
gastrointestinal enzymes in humans and most animals (Burton-Freeman, 2000; Brown, Rosner,
Willett, & Sacks, 1999) with complete or partial fermentation in the large intestine, although a
universal definition is yet to be established (Nugent, 2005). Sources of fiber often include fruits,
vegetables, grain products, legumes, and other sources such as oat and wheat bran (BurtonFreeman, 2000). Fiber can be divided into two groups: soluble fibers that form gels in the
presence of water, or insoluble fibers. The soluble fibers include pectins, gums, mucilages, and
some hemicelluloses, whereas lignins, celluloses, and the remaining hemicelluloses make up the
insoluble fibers (Brown, Rosnar, Willett, & Sacks, 1999). However, the Institute of Medicine
(IOM) suggests categorizing dietary fiber in another manner: by its physiochemical properties
instead. The terms viscous and fermentable are often now used to describe fibers (Queenan et al.,
2007). Other physical properties of dietary fiber include bulk/volume, water-holding capacity,
and adsorption/binding (Burton-Freeman, 2000), with different sources of fiber causing different
bodily responses (Liu et al., 2002). Because of these characteristics and the resulting physiologic
effects, this food group has gained much attention lately from both the public and scientific
communities for its numerous health implications. It has the ability to modify physiologic
function to benefit one’s health, and is thus considered a functional food (Food Nutrition Board,
2001).

5

Dietary fiber has been shown to be positively associated with cardiovascular health. In a
prospective cohort, data showed an inverse relationship between dietary fiber intake and
cardiovascular disease (CVD) and myocardial infarction (Liu et al., 2002). Another prospective
study showed higher consumption of fiber in the diet was correlated with lower concentrations of
C-reactive protein, a marker of inflammation and possible predictor of cardiovascular events.
(Ajani, Ford, & Mokdad, 2004). Soluble fiber has been shown to significantly reduce total
cholesterol levels, as well as low density lipoprotein (LDL): high density lipoprotein ratio (HDL)
(Jenkins et al., 2002). This data plus other scientific evidence further support the reported
negative correlation between fiber and CVD, and the benefit of dietary fiber intake on heart
health.
Research looking at the relationship between consuming fiber and colon health also
seems promising. First of all, fiber normalizes colonic function by increasing fecal weight and
bowel frequency (Correa-Matos et al., 2003). In an international correlative study, starch intake
was inversely related to both colon and rectal cancer (Cassidy, Bingham, & Cummings, 1994). In
a prospective study investigating the relationship between fiber intake and diverticular disease,
both soluble and insoluble fibers were inversely associated with risk of developing diverticular
disease. Insoluble fiber, however, had a stronger inverse relationship (Aldoori et al., 1998).
Doubling fiber intake in populations that consumed very little fiber correlated with up to a 40%
decrease in colorectal cancer risk (Bingham et al., 2003). McBurney (1994) reported that
consumption of fiber in diets for long-term is associated with several changes in the intestinal
milieu, including a change in mass, length, villus appearance, cell proliferation rates, and
enterocyte migration along the crypt-villus axis.
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Diets high in dietary fiber and complex carbohydrates have also been linked to improved
insulinemia. Because of its ability to retard gastric emptying, nutrients in meals consumed with
fiber are absorbed relatively distally in the small intestine, which reduces the amount of gastric
inhibitory polypeptide (GIP) released. GIP is normally secreted in the proximal small intestine,
and is also known to induce insulin release, which can promote hyperinsulinemia (Marshall,
Bessesen, & Hamman, 1997). The fact that it also delays gastric emptying may be beneficial
regarding blood glucose attenuation because of a delayed release of postprandial glucose when
consumed (Nugent, 2005; Queenan et al., 2007)), as well as lowered insulin requirements
(Anderson et al., 1995).
Along with the above mentioned health benefits, the role of fiber in the diet has been
associated with a lower risk of obesity, and it may do so by multiple mechanisms. First of all, it
has been suggested that fiber consumption induces satiety and satiation, mostly due to its bulking
effect (Schneeman & Tietyen, 1994). Research suggests that viscous fibers may delay gastric
emptying, causing a prolonged sensation of fullness, which would result in less consumption of
food (Queenan et al., 2007). Secondly, fiber affects energy density by displacing energy if a
person is consuming a specific volume of food versus a certain amount of energy, which has
been shown in men in a study by Rolls et al (1998). It has also been suggested that dietary fiber
disrupts fat and carbohydrate absorption by delayed gastric emptying, and the interference with
digestive enzymes and the intestinal surface. By this method, fiber would also affect the amount
of calories absorbed (Schneeman & Tietjen, 1994).
The benefits of consuming dietary fiber are quite pronounced in research. In fact, the
consequences of rodents fed diets completely lacking in fiber included atrophy of the small
intestine and colon, with supplementation of the diet with fiber reversing these effects (Slavin,
7

Nelson, McNamara, & Cashmere, 1985; Ecknauer, Sircar, & Johnson; 1981). It seems that
dietary fiber may be beneficial for those at risk for CVD, diabetes, or even obesity. For these
reasons, the National Academy of Sciences recommend 38 and 25 grams of dietary fiber per day
for men and women, respectively (Lupton, 2003).
FERMENTABLE FIBERS AND SHORT CHAIN FATTY ACIDS
Carbohydrates in the colon can affect its physiology by being both physically present or
being the substrate of fermentation (Topping & Clifton, 2001). The microflora of the gut
primarily use carbohydrates as an energy source (Jacobasch et al., 1999). If fiber or starch
somehow bypasses the small intestine, anaerobic fermentation of these fibers by bacteria can
occur in the large intestine, yielding short chain fatty acids (SCFAs), hydrogen, carbon dioxide,
and methane (MacFarlane & MacFarlane, 2003) and metabolizable energy for microbial growth
(Topping & Clifton, 2001). Butyrate, acetate, and propionate are the main SCFAs produced, but
others can be produced in lesser amounts (MacFarlane & MacFarlane, 2003). Colonocytes use
SCFAs as a fuel source, supplying ~60-70% of the colonic energy needs, with butyrate being the
preferred fuel even when glucose is available (Topping & Clifton, 2001). Often propionate is
favored as well, with both formed into ATP for energy for colonocytes (Jacobasch et al., 1999).
The production of SCFAs increases blood flow in the colon, lowers luminal pH, aids in the
prevention of abnormal colonic cell population development (Topping & Clifton, 2001),
regulates colonocytes’ gene expression, cell cycle, and apoptosis, and also exerts trophic effects
on the epithelium of the colon (Mentschel & Claus, 2003). Fermentable fibers can also increase
the abundance of lactic acid bacteria, which further aid in the fermentation of fibers (Russel &
Diez-Gonzales, 1998), and the prevention of potential pathogens that are pH-sensitive,
categorizing them as a prebiotic (Topping & Clifton, 2001). For this reason, they have been
8

added to some oral electrolyte solutions (Oli, Petschow, & Buddington, 1998). Overall, SCFAs
improve the digestive and absorptive capabilities of the colon (Rombeau & Kripe, 1990;
Tappenden et al., 1997). Levels of SCFAs are highest in the proximal colon, where fermentation
is greatest, and levels decrease further down the gut as colonocytes use them, with very little
amounts found in the distal colon. Interestingly, most colon cancers and other colonic diseases
occur in the distal colon, suggesting the importance of SCFAs in colonic health (Topping &
Clifton, 2001). The lowered pH of the lumen upon production of SCFAs is also thought to be
protective against colon cancer (Young & Le Leu, 2004).
Research on fermentable fibers and the resulting SCFAs that are produced verify the
benefits of maintaining the health of the colon. Fermentable fibers can be used to help recover
from diarrhea (Buddington & Weiher, 1999). Correa-Matos et al. (2003) found that consumption
of fermentable fibers reduced the recovery time and improved symptoms of induced S.
typhimurium infection in neonatal piglets indicated by stool consistency and maintenance of
physical activity. It is also believed that SCFAs may help prevent foreign bacteria from
penetrating the small intestine and colon (Reardon & Tappenden, 1999). In dogs fed a diet with
fermentable fibers, it was shown that their intestines were longer, had increased surface area, and
greater mucosal mass compared with those fed a poorly fermentable fiber (Buddington,
Buddington, & Sunvold, 1999).
Data has also shown that fiber-induced fermentation causes the release of particular
gastrointestinal hormones. In canines, glucagon-like peptides (GLP-) 1 and 2, and GIP, which
aid in mucosal growth and upregulation of transport processes in the proximal colon, were all
increased (McBurney et al., 1998). In rats fed fermentable fibers, there was an increase in
intestinal proglucagon (the precursor to glucagon) mRNA and thus greater postprandial GLP-1
9

was released (Reimer & McBurney, 1996), although this increase in proglucagon was not seen in
a later study by Reimer et al. (2000). However, increased concentration of proglucagon-derived
peptides has been observed by others once fermentable fibers were fed (Gee et al., 1996;
Massimino et al., 1998), as well as smaller oscillations in blood glucose concentrations
(Massimino et al., 1998). GLP-1 additionally stimulates insulin secretion, inhibits glucagon
secretion, and delays gastric emptying, all of which are beneficial in diabetic patients (Holst,
1997). The ability of fermentable fibers to promote GLP-1 secretion makes it a target for
treatment in diabetic patients. SCFA production is also associated with an increase in the
gastrointestinal hormone peptide YY (PYY), which has been shown to inhibit gastric emptying
(Cherbut, 1998) and reduce food intake (Batterham, 2003).
The SCFA butyrate particularly has been studied for its role in colonic health. It acts as a
signal metabolite, stimulating cell migration and proliferation (Valezquez, Lederer, & Rombeau,
1996). Research has also shown that butyrate has slightly different functions in neoplastic
colonic cells than in normal epithelial cells. It affects gene expression and may induce apoptosis,
killing off any possible damaged and potentially harmful colonocytes while inhibiting
proliferation (Jacobasch et al., 1999; Mentschel & Claus, 2003), and has been shown to reverse
neoplastic changes in vitro (Ferguson et al., 2000). In normal cells, apoptosis has been observed
in the absence of butyrate (Hass et al., 1997). Segain et al (2000) has also reported that butyrate
inhibits Nuclear Factor-kappa B (NF-κB), a key regulator in inflammatory response. Those
suffering from inflammatory bowel disease have increased activity of NF-κB, suggesting that
butyrate can potentially reduce the immune response. In fact, patients with ulcerative colitis and
colon cancer have been reported to have low levels of butyrate (Chapman et al., 1994).
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Concerning weight management, butyrate has been reported to increase gene expression of PYY
and proglucagon and may participate in satiety (Zhou et al., 2006)
Research also suggests that other SCFAs can be beneficial for health. Propionate has
been shown to suppress fatty acid and cholesterol synthesis in vitro (Berggren, Nyman, &
Lundquist, 1996) and in vivo (Chen et al., 1984), although this is not agreed by all (Queenan et
al., 2007). Propionate is also confirmed to kill E. coli in an acidic environment (Cherrington et
al., 1991). Acetate has been shown to decrease free fatty acid availability in humans and inhibit
cholesterolgenesis in rats (Beynen, Buechler, & Van Der Molen, 1982), and Abrahamse et al
(1999) reported that acetate inhibits DNA oxidative damage due to H2O2 in the rat colon. Both
propionate and acetate have been observed to induce apoptosis like butyrate in tumorigenic cells.
However, they do so to a lesser extent and require higher concentrations (Hague et al., 1995).
Butyrate, propionate, and acetate have all been associated with greater colonic blood flow
(Mortensen et al., 1991; Kvietys & Granger, 1981), enhancing tissue oxygenation and transport
of absorbed nutrients (Topping & Clifton, 2001).
Any fermentable fibers or starches that produce SCFAs, especially butyrate, thus may be
targeted for improving gut health and preventing possible pathology from developing. The
delivery of butyrate to the distal colon may be particularly important because of its susceptibility
to diseases relative to the proximal colon (Topping & Clifton, 2001). The effect of SCFAs on
hormone secretion, particularly GLP-1 and PYY, is of great interest regarding weight
management.
RESISTANT STARCH
Starch is the polysaccharide storage form of glucose found in plants, and is a major
source of carbohydrates in the diet (Nugent, 2005; Sajilata, Singhal, & Kulkarni, 2006). It is
11

packaged as granules in two forms: the polymer amylose consisting of linear glucose residues
connected by α-D-(1-4) linkages, or the branched polymer amylopectin consisting of the same
linear α-D-(1-4) linkages plus branched α-D-(1-6) linkages. Starch is usually hydrolyzed by the
enzymes α-amylases, glucoamylase, and sucrose-isomaltase in the small intestine (Nugent,
2005); however, this is not the case for all starches. In 1982, Englyst and colleagues found that
not all starch was hydrolyzed by enzymes, and this remainder was termed “resistant starch”
(Englyst, Wiggins, & Cummings, 1982). Resistant starch, as the name implies, refers to the
portion of starch that resists digestion into free glucose and absorption in the small intestine,
bypassing it and reaching the large intestine where it is fermented by colonic microflora. This
fermentation process, like dietary fiber, results in the production of SCFAs (butyrate, acetate,
and propionate), as well as carbon dioxide, methane, hydrogen, and organic acids. However,
unlike dietary fiber, fermentation of RS produces more butyrate and less acetate (Nugent, 2005;
Sajilata, Singhal, & Kulkarni, 2006).
Resistant starch (RS) is resistant to mammalian enzymes due its structure, and four types
exist: RS1, RS2, RS3, and RS4. RS1 refers to a physically inaccessible form of starch that is
physically protected because the intact plant structure of amyloblasts hinders enzymatic
degradation. RS2 refers to starch in a certain granular form that is tightly packed in a radial
pattern, limiting its accessibility to enzymes. RS3 refers to retrograded amylose formed during
cooling of gelatinized starch, and is the most resistant form of RS by mammalian digestive
enzymes, but still degradable by microbial fermentation. Finally, RS4 refers to the formation of
new chemical bonds other than the α-D-(1-4) and α-D-(1-6) linkages found in starch (Jacobasch
et al., 1999; Sajilata, Singhal, & Kulkarni, 2006), and includes starches that have been etherized,
esterified, or cross-bonded with chemicals that reduce their digestibility (Nugent, 2005). Natural
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food sources of RS include bananas and legumes (Sajilata, Singhal, & Kulkarni, 2006), and can
be found in some amounts in any food containing starch (Nugent, 2005). Most humans tend to
consume RS from cooked sources, such as cooked potatoes, breads, and pastas, and these natural
sources are usually affected by processing and storage conditions. Commercially available
sources of RS, on the other hand, such as Hi-maize® or CrystaLean® (Nugent, 2005), are
unlikely to be affected by such conditions (Sajilata, Singhal, & Kulkarni, 2006). The commercial
sources have other advantageous properties that make them useful for incorporating into food
products, including bland in flavor, fine particle size, increasing the bowl life of breakfast
cereals, and being a functional food component. And just as there are different forms of RS, each
form may have a slightly different physiological response. Also the amount consumed, what else
was consumed at the time, and the cooking conditions all may affect the physiological response
as well (Nugent, 2005).
In addition to these forms affecting the resistance of starch, a higher ratio of
amylose:amylopectin also lowers the digestibility of starch, with the linear amylose chains
forming a packed structure of cross linkages secured by hydrogen bonds upon retrogradation.
Amylopectin can interfere with this structure formation during retrogradation (Berry, 1986).
Repeated cycles of heating then cooling can increase the retrogradation process (Annison &
Topping, 1994). Cooking can also affect the RS content in food, with high moisture and
temperature processes disturbing the crystalline structure of RS, thus lowering the content
(Sajilata, Singhal, & Kulkarni, 2006). Another factor influencing RS is the addition of
endogenous lipids, which can complex with amylose and possibly disrupt the formation of RS
(Eerlingen et al., 1994). Finally, fermentation can reduce the content of RS, as is the case in the
large intestine when it is broken down by the gut microflora.
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Although it is a starch, RS shares similar physiologic properties and health benefits with
soluble fiber, as well as benefits unique to its own as an insoluble component of the diet. Both
RS and soluble fiber are slow to digest, with RS digestion usually occurring 5-7 hours after
consumption, and result in slower, more controlled glycemic response and lowered postprandial
insulinemia and potentially increasing satiety (Jenkins et al., 1987; Raben et al., 1994). This
response is most likely due to the replacement of digestible starch found in other foods with the
indigestible starch (Jenkins, 2002). RS and soluble fiber are both poorly digested in the small
intestine, but highly fermented in the large intestine with SCFA production (Bjorck et al., 1987;
Goni et al., 1996; Sajilata, Singhal, & Kulkarni, 2006). RS, however, is not viscous like soluble
fiber upon arrival in the large intestine (Nugent, 2005), and has been reported to produce a larger
proportion of butyric acid than fiber does (Akerberg et al., 1997). It is estimated that about 3070% of RS is metabolized in the colon with the remainder excreted (Behall & Howe, 1995).
Data supports that RS confers several health benefits. It has been shown to be beneficial
to the colonic milieu, including increasing crypt cell production rate, decreasing large intestinal
cell atrophy (Sajilata, Singhal, & Kulkarni, 2006), increasing fecal weight and output, reducing
fecal and cecal pH (Cassand et al., 1997), decreasing ammonia levels, and altering the activity of
bacterial enzymes in a beneficial manner (Silvi et al., 1999) relative to a lack of fiber. Butyrate
produced from fermentation of RS is an energy substrate for colonic cells and has been shown to
inhibit malignant transformation of colonic cells in vitro (Asp & Bjorck, 1992). RS has also been
studied as a treatment option for ulcerative colitis. In a study by Jacobasch et al (1999), rats with
chemically induced colitis and fed RS showed earlier sign of improvement for markers of
inflammation compared to controls. Studies show that RS affects expression of a number of
receptors on T- and B- lymphocytes and macrophages, which are all involved in immune
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function (Sotnikova et al., 2002), and inhibits NF-κB through butyrate production (Segain et al.,
2000). The noted impact on immune response may be of interest regarding inflammatory bowel
disease. Because of its tendency to affect the microbial population, RS may also function as a
prebiotic stimulating the growth of beneficial bacteria of the gut while suppressing the
pathological ones (Young & Le Leu, 2004; Sajilata, Singhal, & Kulkarni, 2006).
Beyond the colon, RS, like fiber, has also been linked to reduced serum cholesterol and
triglyceride levels in animal models (Younes et al., 1995; Mathe et al., 1993) and human subjects
(Behall, Scholfield, Yuhaniak, & Canary, 1989; Behall & Howe, 1995). Consumption of RS has
been associated with decreased incidence of gallstones as well (Malhotra, 1968). Like dietary
fiber, it is associated with decreased postprandial glucose and insulin responses, which would be
of particular interest in diabetic treatment (Haralampu, 2000).
In addition to its numerous health implications, several studies have supported the use of
RS as a treatment option for weight management. Results from several animal studies indicate
that consumption of RS may lead to weight loss or reduced weight gain. For example, De
Deckere et al (1993) reported lowered fat pad weight and decrease adipocyte cell size, and this
has been confirmed by other studies (Lerer-Metzger et al., 1996; Kabir et al., 1998a)
Consumption of RS was associated with a decrease in GLUT-4 expression, an insulin-regulated
protein responsible for glucose uptake (Kabir et al., 1998b). Younes et al (1995) reported a
decrease in the activity of lipogenic enzymes 3-hydroxy-3-methylglutaryl-Co A and fatty acid
synthase, which are involved in cholesterol synthesis and fat synthesis, respectively. Another
study has shown that RS increases the expression of the LDL receptor in the liver of rats
(Fukushima, 2001). Mathe et al (1993) demonstrated that RS increased bile acid secretion, which
can also affect lipid metabolism. Recently, Keenan et al (2006a) reported that RS-fed rats had
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lower abdominal fat relative to a control group, even though their food intake was not different
from the control.
There are a few possible leads as to how RS affects body weight. Most of the research
involved in this area focuses on the anaerobic bacterial fermentation of RS into SCFA, and it is
through these acids that RS is thought to help in limiting weight gain (Topping, Fukushima, &
Bird, 2003). When compared to a non-fermentable fiber, RS had greater amounts of SCFAs
produced, along with increased transcription of PYY and proglucagon, and increased plasma
levels of PYY and GLP-1 (Keenan et al., 2006). PYY is normally released in the gut in
proportion to the amount of calories ingested (Adrian et al., 1985) and is a gut-signaling
hormone indicating food intake in the brain (Batterham, 2002). As stated earlier, PYY has been
shown to reduce food intake and weight gain when infused in human subjects, and lower
endogenous PYY levels have been observed in obese subjects (Batterham et al., 2002). Longterm administration of PYY in murine models has demonstrated decreased weight gain
(Batterham, 2003). GLP-1 is also released in response to food ingestion (Deacon, 2005), and acts
as a meal termination signal and food regulation (Kreymann et al., 1987; Flint, Raben, Astrup, &
Holst, 1998). With the increase of these two peptides, it is suggested that the RS-produced
SCFAs are a natural and endogenous method to reduce energy intake and hopefully body weight
(Keenan et al., 2006a).
Although SCFA production in relation to RS fermentation is highly studied, other
putative mechanisms may also be responsible for its role in weight management. First of all, the
metabolizable energy value of RS has been calculated to be ~2 kcal/g, whereas digestible
carbohydrates have an energy value of ~4 kcal/g (Livesey, 1994). This displacement of kcals by
the addition of RS in the diet can displace the total amount of kcals consumed in a day, thus
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resulting in a decreased overall caloric intake, just as with dietary fiber. Higgins et al (2004)
reported that replacing 5.4% of total carbohydrates with RS in the diet could increase
postprandial lipid oxidation. They suggest that this mechanism could help reduce fat
accumulation in the long term. Also, foods rich in RS may cause a reduced insulin response due
to its lowered glycemic response. Ultimately, this may make fat more accessible for energy use
(Tapsell, 2004). It has been suggested that RS may also promote satiety, although this is still
controversial (Nugent, 2005). These examples are supplementary ways as to how RS may work
in the treatment of obesity and in weight management.
Overall, research agrees that the effects of RS are advantageous to the body with much
potential nutritional and commercial value (Asp, Amelsvoort, & Hautvast, 1996). It has a wide
range of influence, affecting fermentation in the gut, fecal bulking and transit time, colonic
bacterial growth, postprandial glycemia and insulinemia, and energy value of foods (Abia et al.,
1993; Annison & Topping, 1994). However, there are some concerns with consumption of RS
regarding bloating, flatulence, belching, mild laxative effects and stomach aches when RS is
consumed in larger amounts (~30g/day or more) (Heijnen, 1996). Other than these discomforts,
the potential physiological benefits of RS are obviously similar to dietary fiber, although it is
considered a starch. And it is because of these similarities that deem it worthy of being
categorized as a component of dietary fiber to some (De Vries, 2003). Data also confers that RS
as part of the diet can be used in weight loss and/or management. And although RS does produce
energy through fermentation, this energy value is still less than digestion of starch in the small
intestine (Englyst, Kingman, Hudson, & Cummings, 1996). Whether this starch’s influence on
body weight and body fat is solely due to the production of SCFAs upon fermentation and the
subsequent increase in PYY and GLP-1, or other mechanisms is not yet clear. More research is
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needed to distinguish its exact manner, but for now its use in the treatment of obesity seems
extremely promising.
ENDOCRINE OBESITY
Overweight and obesity are growing problems worldwide, with numerous factors
contributing to their cause. Increased energy intake and decreased energy output are often the
blame for the sudden epidemic. Increased fat accumulation due to endocrine changes is a lesser
known cause of obesity, but may also be responsible for the increased rates due to its resulting
metabolic alterations. Particularly, the hormone estrogen has been investigated for its role in
energy homeostasis.
It is well understood that the postmenopausal period is related to a striking change in
endocrinology (Burger et al., 1995). In postmenopausal women, the ovaries lose their ability to
function, including the production and release of estrogen (Danilovich et al., 2000). It has been
known for some time that the decrease in estrogen production that results during menopause is
followed by a characteristic increase in body fat (Shimizu et al., 1997; Toth, Tchernof, Sites, &
Poehlman), with fat accumulation occurring more likely in the upper body, mainly the abdominal
area, rather than lower (Tremollieres, Pouilles, & Ribot, 1996; Gambacciani et al., 1996) putting
the postmenopausal woman at increased risk for developing CVD and diabetic complications
(Lean, Han, & Seidell, 1998). In fact, postmenopausal women have 20% more body fat
compared to premenopausal women (Ley, Lees, & Stevenson, 1992).
In the murine model, lack of estrogen production can modify metabolism resulting in
obesity, skeletal abnormalities, and infertility (Danilovich et al., 2000). The ovariectomy
procedure in rats ceases estrogen production and imitates the symptoms of menopause. This
procedure has been shown to increase body weight by many (Kakolewski, Cox, & Valnstein,
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1968; Ainslie et al., 2001), and was reported to do so by 22% in just 10 weeks (Kakolewski,
Cox, & Valnstein, 1968). In one study that disrupted the follicle-stimulating hormone receptor
(FSH-R) in mice by using a knockout model, which also terminates estrogen production, an
increase in abdominal fat deposition, curvature in the spinal column, and a decrease in bone
weight all occurred. Replacement of estrogen in these knockout mice reversed the adipose
accumulation (Danilovich et al., 2000). Mice of both sexes that have the estrogen receptor-alpha
knocked-out display increased white adipocyte tissue (WAT) and hyperplasia (Heine et al.,
2000). Another study showed that mice deficient in aromatase, the enzyme responsible for the
production of estrogen, developed fatty livers and had more abdominal adipose tissue. The study
concluded that the fat accumulation was a result of a combination of reduced physical activity
and glucose oxidation (Jones et al., 1997). Ainslie et al (2001) reported that ovariectomized rats
were hyperphagic, had lower levels of spontaneous physical activity, and a similar resting energy
expenditure compared to sham-operated rats, all of which resulted in weight gain.
Ovariectomized rats treated with estradiol had similar body weights, energy intakes, and physical
activity levels to that of sham rats.
Clinical studies in humans also agree that estrogen does have an effect on body weight. A
cross-sectional study and a prospective, double blind, placebo-controlled study showed an
increase in body mass index (BMI) and body weight, respectively, as menopause transitioned
(Burger et al., 1995; Pepi, 1995). Bjorkelund et al (1996) also reported an increase in waist-tohip ratio between the pre- and postmenopausal periods in their longitudinal study. This increase
in body weight, and particularly body fat, has been seen by many (Hunter et al., 1996; Zamboni
et al., 1992; Kontani et al., 1994). Stevenson et al (1994) demonstrated that hormone
replacement therapy (HRT) with estradiol in postmenopausal women prevented abdominal
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weight gain, and Dellongeville et al (1995) described a lowering of BMI once treated with HRT.
Another study with newly postmenopausal women found that those on HRT had no significant
weight gain, while those on simply a calcium supplement had a significant increase in body fat
weight, with most of the weight gain occurring in the trunk and the arms (Gambacciani et al.,
1996).
Not only is there clear evidence of fat accumulation with the onset of menopause, some
believe that there is in fact a loss of fat free mass. Poehlman et al (1995) noted an average 3 kg
loss of fat-free mass in women between their premenopausal and postmenopausal periods in a
longitudinal study. Others suggest that there is predominantly a loss in skeletal muscle mass
(Poehlman et al., 1993; Aloia et al., 1991). Toth et al (2000), however, did not see this similar
loss in fat free mass.
Menopause and loss of estrogen production may also be associated with type 2 diabetes,
possibly due to weight gain. Considering estrogen’s reversal effect on fat accumulation in former
studies, research looked at its possible role in treatment of diabetes. Simply knocking out the
estrogen receptor resulted in insulin resistance and glucose intolerance (Heine et al., 2000). In
one study, estrogen treatment was shown to increase cell surface insulin receptor number in
ovariectomized rats, which increased insulin binding and receptor-mediated insulin degradation
(Krakower, Meier, & Kissebah, 1993). Geisler et al (2002) reported inhibition of both weight
gain and hyperglycemia in a male mouse model prone to hyperglycemia when treated with
estradiol. In postmenopausal women, estradiol treatment increased secretion of pancreatic insulin
and decreased insulin resistance (Stevenson et al., 1994). In men unable to produce estrogen,
insulin resistance ensued (Grumbach & Auchus, 1999).
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Cardiovascular complications are also a concern with the onset of menopause and the
central body obesity that results. Stevenson et al (1994) suggest that HRT in postmenopausal
women can reduce coronary heart disease by 50%. In another study, hyperlipidemia was shown
to result in men with estrogen insufficiency (Grumbach & Auchus, 1999).
The means by which estrogen plays a role in energy homeostasis may work via various
hormones. In the rat model, ovariectomy was shown to decrease mRNA levels and serum
concentrations of leptin (Shimizu et al., 1997), which signals to the brain decreased fat mass and
results in a hyperphagic state as well as decreased energy expenditure (Mantzoros, 1999). Once
again, estradiol treatment reversed these effects (Shimizu et al., 1997). Ainslie et al (2001),
however, did not find decreased secretion of leptin in ovariectomized rats, and Pelleymounter et
al (1999) also reported no alteration in leptin levels with either ovariectomy or estradiol
treatment. Besides leptin, lack of estrogen in the ovariectomized rat model has been shown to
increase hypothalamic neuropeptide Y (NPY) mRNA expression, which stimulates food intake
and may have a role in excess fat accumulation as well (Shimizu et al., 1996; Ainslie et al.,
1999).
Considerable evidence has shown that estrogen indeed plays a role in energy metabolism,
and disruption of estrogen synthesis has been shown to result in fat accumulation. Data reports
that this weight gain can be blunted or even reversed if estrogen is once again provided,
suggesting that it is the deficiency of estrogen that is responsible for the weight gain during the
postmenopausal period.
HIGH FAT DIETS
Much attention regarding the amount of fat in the diet has been received lately in relation
to weight gain and the prevalence of obesity. High fat diets are often to blame for inducing
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obesity. Fat has a higher energy density relative to the other macronutrients, and is considered
more palatable, which can easily lead people to consume more. Overall, this combination can
lead to a greater energy intake relative to output (Seidell, 1998; Willet, 1998). A “westernized”
diet that is highly processed, high in fat, cholesterol, refined sugar, and alcohol, and low in fruits
and vegetables has been adopted in the United States and most Western countries (Cordain et
al., 2005). Although dietary fat cannot be the sole responsibility of the obesity epidemic, it is a
major concern in today’s unbalanced diet. And although the body has regulatory systems that
attempt to maintain body weight, Woods et al (2003) explain, “that when individuals are
exposed, on a chronic basis, to a higher mean level of dietary fat, the otherwise incredibly robust
negative feedback system that regulates body fat decreases. More fat is stored and the individual
moves along the scale toward obesity.” Reducing fat intake is a difficult task, especially since fat
is often used in foods for its palatability and ability to increase shelf life.
Weight gain and fat accumulation are the most common associations with diets high in
fat, but there are certainly other adverse health effects that are linked to high fat diets.
Epidemiologic studies have shown that diets high in total and saturated fat have been associated
with fasting hyperinsulinemia (Maron, Fair, & Haskell, 1991; Parker et al., 1993; Mayer,
Newman, Quesenberry, & Selby, 1993) and have been shown to cause insulin resistance in rats
(Storlein et al., 1986). As explained earlier, diets high in dietary fiber control insulin release by
reducing the amount of secreted GIP, and RS is likely to have the same effects to counter this
with high fat diets.
Epidemiologic data support the relationship between higher fat consumption and weight
gain. The observation of migrants who have adopted the western diet and the concomitant weight
gain and disease states that are not normally seen in their native countries has further elucidated
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the consequences of this eating pattern. The prevalence of obesity was reported to be three times
as high in Japanese men living in California relative to their Japan-inhabited counterparts (Kato
et al., 1973). The Pima Indians are another prime example of the deleterious effects of a
westernized diet that is cheap, palatable, and high in fat (Schrauwen & Westerterp, 2000). Those
that still live in Mexico maintain their traditional eating habits and lifestyle, while those living in
Arizona are exposed to the convenience of more processed foods high in refined sugars and fat,
and less physically-active occupations. The latter group now has a high prevalence of obesity
and type 2 diabetes from their exposure to this environment (Esparza et al., 2000). In a
longitudinal analysis, Klesges et al (1992) reported that women with higher fat intake were
related to higher weight gain.
Animal models and clinical trials have associated higher fat diets with weight gain and fat
accumulation. When rats were given free access to a high fat diet, they became obese compared
to those on a diet with the same composition except for less fat (Woods et al., 2003). In a study
by Lissner et al (1987), women fed a high fat diet (45-50%) gained weight relative to a medium
fat diet (30-35%), and those fed a low fat diet (15-20%) experienced weight loss. In another
study by Jeffery et al (1995) comparing fat restriction with energy restriction, results concluded
that a low fat diet had similar weight loss but better compliance among subjects. Higher fat
intake and weight gain or increased adiposity has been supported by others as well (Tremblay,
Plourde, Despres, & Bouchard, 1989; Tucker & Kano, 1992).
The relationship between high fat diets and the prevalence of obesity has been observed
for quite some time. The extreme conversion into an industrialized society has not permitted our
genetics to adjust to all it entails, including lifestyle and eating habits (Cordain et al., 2005). In
addition to obesity, high fat diets are related to an assortment of other co-morbidities including
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heart disease and type 2 diabetes. The amount of fat alone is not only important to a healthy
lifestyle, but the type of fat should also be considered, with more effort in consuming sources of
unsaturated fatty acids and less intake of saturated and trans fats (Willet, 1998; Cordain et al.,
2005). It is imperative to find ways to treat overweight and obesity in an effective method that
tailors to the needs and lifestyle of people today.
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CHAPTER 3
METHODS
EXPERIMENTAL DESIGN
For both studies, a 2x2 factorial design was used to examine the effects of resistant starch
on the body weight, body fat, food intake , peptide-YY (PYY) levels, and glucagon-like peptide1 (GLP-1) levels in rats.
Study 1. The effects of resistant starch were compared in rats fed a high fat diet (44.8%
of energy, 22% fat w/w) to those fed a low fat diet (17% of energy, 7% fat w/w). Half of the rats
fed the high fat diet (HF) were assigned to a diet high in resistant starch (RS), and half were
assigned to an energy control diet (EC). Half of the rats fed the low fat diet were assigned to a
diet high in resistant starch, and half were assigned to an energy control diet (Table 3.1).
Study 2. An endocrine model of obesity, ovariectomy, was used to test the effects of
resistant starch. To control for the effects of surgery a sham surgery arm of the 2 X 2 factorial
was used. Half of the ovariectomized and sham rats were assigned to a diet high in RS, and half
were assigned to an EC diet (Table 3.2).

Table 3.1 2x2 Factorial Design, Study 1 (n=40)
FAT
STARCH HF Diet LF Diet
EC Diet

10

10

RS Diet

10

10
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Table 3.2 2x2 Factorial Design, Study 2 (n=40)
SURGERY
STARCH OVX Rats SH Rats
EC Diet

10

10

RS Diet

10

10

ANIMALS
For both studies, rats were maintained on a 12:12 hour light/dark cycle that was
illuminated at 7AM. Water and powdered diet were available ad libitum during the experiment.
All of the diets were a modification of the American Institute of Nutrition-93 Growing diet
(AIN-93G) for growing rats.
Study 1. Forty, 7 week old male Sprague-Dawley rats were used.
Study 2. Forty female Sprague-Dawley rats were used. Twenty of the rats underwent
surgery to remove the ovaries, and 20 underwent a sham operation to equate the physiological
stress that results from ovariectomy surgery. The surgery was performed on the rats at 10 weeks
age by the supplier, Harlan (Indianapolis, IN).
HOUSING
All animals were housed in stainless steel cages with wire mesh bottoms to
account for food spillage, and with wire mesh fronts in order to view the animals. The powdered
diet was placed in glass food jars by the experimenter, and secured by a wire spring that attached
to the wire mesh front of the cage. Water was available via a water nozzle at the back of the cage
that released water when it is pushed on. Cardboard sheets were set under each animal’s cage to
capture any food spillage for later measurement.
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PROCEDURES
Study 1.
Diet Preparation. To prepare each diet, macronutrients (without fat) were measured and
combined in a large mixing bowl. The macronutrients were mixed for 10 minutes.
Micronutrients were then measured, combined in a small mixing bowl with food coloring if
necessary, and mixed for 10 minutes. One scoop of the macro mix was then added to the micro
mix in the small mixing bowl, and mixed for 10 minutes. Then this micro mix was added to the
large mixing bowl and mixed for 10 minutes to evenly distribute the ingredients. Oil or oil/solid
fat was then measured and added to the mix, and mixed for 30 minutes. The diet was stored in
labeled containers in refrigerators and freezers. The label included diet type, date of preparation,
and researcher’s name. Ten kilogram batches were made at a time.
The rats were randomly assigned to a low fat control diet, low fat resistant starch diet,
high fat control diet, or high fat resistant starch diet. Resistant starch was used in the form of HiMaize® cornstarch (National Starch, Bridgewater, NJ). The compositions of the diets are listed
in Table 3.3. The energy breakdown of the diets is listed in 3.4.
Table 3.3. Diet Composition Table for LFEC, LFRS, HFEC, HFRS to make a 10 kg Batch
INGREDIENTS

LFEC

LFRS

HFEC

HFRS

Amioca (g)

5347

1500

3847

-

Hi-Maize (g)

-

4807

-

4807

Sucrose (g)

500

500

500

500

Casein (g)

2000

2000

2000

2000

Macro Mix

(Table Continued)
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Cellulose (g)

960

-

960

-

Mineral Mix (g)

350

350

350

350

Vitamin Mix (g)

100

100

100

100

Choline Chloride (g)

13

13

13

13

L – Cystine (g)

30

30

30

30

700

700

1000

1000

1200

1200

Micro Mix

Oil Mix
Vegetable Oil (g)
Lard (g)
BHT (g)
TOTAL

0.140

0.140

0.140

0.140

10000 g

10000g

10000g

10000g

Table 3.4. Caloric Composition of the LFEC, LFRS, HFEC, and HFRS diets as % (g/100g)
Nutrient

LFEC

LFRS

HFEC

HFRS

21

21

21

21

Total Carbohydrates

61.9

61.9

61.9

61.9

Fat

17.1

17.1

44.8

44.8

Kcal/g of Food

3.5

3.5

4.2

4.2

Protein

Week 1: Acclimation Period. All animals were fed a low fat control diet for one week to
become acclimated to the powdered diet and environment. The weight of the animal, the weight
of the empty food jar, the weight of the full food jar, and the food spillage were measured three
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times a week (Monday, Wednesday, and Friday) for each animal. After measurements were
taken for empty food jar weights, the food jars were refilled and full jar weight was recorded.
Week 2: Group Assignment. After the acclimation period, the animals’ weights were
used to determine group assignment. The animals’ weights were put into ascending order and
then ordered into four blocks of 10 replicates. The animals were assigned to one of four
treatment groups by choosing one from each block at a time. The result was that the average
weight for each group was within one-tenth of a gram of one another.
Weeks 2 through 14: Treatment. Throughout the experiment, the animals’ weights, the
empty food jar weights, the full food jar weights, and the food spillage were measured every
Monday, Wednesday, and Friday beginning between 12PM-2PM. Empty food jars consisted of
the leftover food in the food jar. Full food jar consisted of the weight of the food jar once it was
refilled with the powdered diet. Every Monday, food jars were switched for clean food jars, and
any leftover diet in the food jar was thrown out for fresh diet. Throughout the experimental
period, animals were switched to new cages every two weeks for sanitary reasons. The animals
were fed on their assigned diets for 12 weeks. Body fat of the animals was measured using the
nuclear magnetic resonance (NMR) method at the beginning, middle and end of the treatment
period.
Week 15: Sacrifice. The animals were sacrificed via decapitation. Due to the large
number of animals, the sacrifice took place over 2 days between days, spaced 2 days apart.
Tissues that were collected included blood samples, brain, scrapings of the top cellular layer of
the cecum, cecal content samples, peri-renal fat, epididymal fat, and retroperitoneal fat.
Measurements that were taken included the entire gastrointestinal tract weight with contents, full
cecum weight, empty cecum weight, peri-renal fat weight, epididymal fat weight, and
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retroperitoneal fat weight. The ceca were gently rinsed with a saline solution to remove any
contents before empty ceca weights were taken. Cecal contents were stored in the freezer. Brains
were frozen on dry ice, blood was kept cold on ice before plasma separated by centrifugation and
stored in the freezer, and cecal scrapings were stored in foil and frozen in liquid nitrogen during
the sacrifice until the tissues could be stored in the freezer.
Cecal contents were used to analyze pH.
Study 2.
Diet Preparation. The same diet preparation procedure used in Study 1 was also used in
Study 2.
The rats were randomly assigned to either the energy control diet or resistant starch diet
from the ovariectomized or sham surgery groups. The compositions of the diets are listed in
Table 3.5. The energy breakdown of the diets is listed in Table 3.6.
Table 3.5. Diet Composition Table for EC and RS diet to make a 10 kg Batch
INGREDIENTS

EC

RS

Amioca (g)

4245

-

Hi-Maize (g)

-

5307

Sucrose (g)

1000

1000

Casein (g)

2000

2000

Cellulose (g)

1562

500

350

350

Macro Mix

Micro Mix
Mineral Mix (g)

(Table Continued)
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Vitamin Mix (g)

100

100

Choline Chloride (g)

13

13

L – Cystine (g)

30

30

Vegetable Oil (g)

700

700

BHT (g)

0.140

0.140

10000g

10000g

Oil Mix

TOTAL

Table 3.6. Caloric Composition of the EC and RS diets as % (g/100g)
EC
Nutrient

RS

%(g/100g) %(g/100g)

Protein

21

21

Total Carbohydrates

61.9

61.9

Fat

17.1

17.1

Kcal/g of Food

3.3

3.3

Weeks 1 through 6: Acclimation Period. All animals were fed a control diet for four
weeks to become acclimated to the powdered diet and environment. The weight of the animal,
the weight of the empty food jar, the weight of the full food jar, and the food spillage were
measured three times a week (Monday, Wednesday, and Friday) for each animal. After
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measurements were taken for empty food jar weights, the food jars were refilled and full jar
weight was recorded.
Week 7: Group Assignment. After the acclimation period, the animals’ weights were
used to determine group assignment. The animals’ weights were put into ascending order within
ovariectomized and sham surgery groups. The weights were then ordered into two blocks of 10
replicates per surgery type. The animals were assigned to one of four treatment groups by
choosing one from each block at a time. The result was that the average weight for each of the
two ovariectomized groups was within one-tenth of a gram of one another; and the same for the
two sham groups.
Week 7 through 19: Treatment. Throughout the experiment, the animals’ weights, the
empty food jar weights, the full food jar weights, and the food spillage were measured every
Monday, Wednesday, and Friday beginning between 10AM-12PM. Empty food jars consisted of
the leftover food in the food jar. Full food jar consisted of the weight of the food jar once it was
refilled with the powdered diet. Every Friday, food jars were switched for clean food jars, and
any leftover diet in the food jar was thrown out for fresh diet. Throughout the experimental
period, animals were switched to new cages every two weeks for sanitary reasons. The animals
were fed on their assigned diets for 12 weeks.
Body fat of the animals was measured using the NMR method at the beginning, middle
and end of the treatment period.
Week 19: Sacrifice. The animals were sacrificed via decapitation. Due to the large
number of animals, the sacrifice took place on two consecutive days. Tissues that were collected
include blood samples, brain, cecal scrapings, cecal samples, peri-renal fat, epididymal fat, and
retroperitoneal fat. Measurements that were taken included entire gastrointestinal tract weight,
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small intestine weight, full cecum weight, empty cecum weight, perirenal fat weight, ovarian fat
weight, mesentaeric fat weight, and retroperitoneal fat weight. The ceca were gently rinsed with
a saline solution to remove any cecal contents before empty ceca weights were taken. Cecal
contents were stored in the freezer. Brains were frozen on dry ice, blood was kept cold on ice
before plasma separated by centrifugation and stored in the freezer, and cecal scrapings were
stored in foil and frozen in liquid nitrogen during the sacrifice until the tissues could be stored in
the freezer.
For analysis of tissues, the animals’ brains were removed from the freezer to isolate the
arcuate nucleus of the hypothalamus and extract the total RNA from the arcuate. Then the the
mRNA expression for proopiomelanocortin in the arcuate nucleus of the hypothalamus was
determined releative to the housekeeping gene cyclophilin. The cecal scrapings were used to
analyze the mRNA expressions for PYY and GLP-1.
CONSTRUCTS AND VARIABLES
Weight of Rats. Animals were measured in a bucket on a balance that was tared to zero
before the animal was put in. The weight was measured in grams, and rounded to the nearest
gram.
PYY Levels and GLP-1 Levels. Total peptide YY (PYY), total glucagon-like-peptide-1
(GLP-1), and active GLP-1 were assayed with radioimmunoassay kits from Millipore (St.
Charles, MO).
Amount of Food Consumption. Food consumption was calculated by subtracting the
empty food jar weight and food spillage weight of the current day’s measurement from the full
food jar weight of the previous day’s measurement. Empty food jar weights were measured on a
balance, and measured in grams rounded to the nearest gram. The food jars were then refilled
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with the appropriate diet. Full food jar weights were measured on the balance in grams, rounding
to the nearest gram. Food spillage was accounted for by removing any feces from the cardboard
sheet, and weighing the leftover food spillage. The spillage was measured in a weigh boat that
was tared to zero before the food was put in. Total food consumed for each rat was measured
every Monday, Wednesday, and Friday.
Cecal Content pH. The pH of the cecal contents was determined by homogenizing
thawed cecal contents in distilled water (0.5 g wet sample to 5 ml water), and the pH was
measured using a combination electrode. The samples were acidified with 1 ml of a 25 % (w/w)
solution of meta-phosphoric acid that contained 2g/l of 2-ethyl-butyric acid as an internal
standard for the short chain fatty acid contents. Solids in the homogenized samples were
separated by centrifugation. Short chain fatty acids in the effluent were analyzed using gas-liquid
chromatography.
Body Fat. Total body fat was determined using the NMR method. One at a time, each
animal was inserted into Bruker’s minispec Lean/Fat Analyzer for measurement. Each animal
was measured twice, and the average of the two body fat percentages was used. NMR
measurement was taken three times during each study: once before treatment started, once six
weeks after treatment began, and once before sacrifice. Upon sacrifice, abdominal fat pad
weights were also collected and measured.
STATISTICAL ANALYSIS
Data were analyzed using the Statistical Analysis System (SAS) statistical software
package version 9.1. A 2x2 factorial was performed for all measurements. Results were
considered statistically significant if p<0.05.
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CHAPTER 4
RESULTS
STUDY 1
Cumulative food intake was higher for LF rats relative to HF rats (LFEC, 593; LFRS,
612; HFEC, 499; HFRS, 482 ± 14.85 grams, p<0.0001) (Fig. 4.1), but energy intake remained
the same among all treatment groups (LFEC, 2077; LFRS, 2142; HFEC, 2085; HFRS, 2017 ±
56.3 kJ) (Table 4.1). HF rats did have an increase in body weight compared to LF rats (LFEC,
366; LFRS, 383; HFEC, 397; HFRS, 402 ± 7.84 grams, p<0.0027) (Table 2). Disemboweled
body weight was higher in the HF rats (LFEC, 351; LFRS, 357; HFEC, 383; HFRS, 387 ± 6.05
grams) compared to LF rats (p<0.0001) (Table 2). Full cecum (p<0.0001) and empty cecum
weights (p<0.0001) were higher in RS rats compared to EC rats, and higher in LF rats compared
to HF rats (Table 4.1), with LFRS rats having significantly higher full and empty cecum weights
relative to the other groups. This resulted in a significant fat x diet interaction. Epididymal fat
(p<0.0001), abdominal fat (p<0.0001), perirenal fat (p<0.0003), and the total fat (LFEC, 8.33;
LFRS, 8.34; HFEC, 11.43; HFRS, 12.59 ± 0.66 grams, p<0.0001) were also higher in the HF rats
compared to the LF rats (Table 4.1). Plasma PYY was higher in RS rats compared to EC rats
(LFEC, 132.6; LFRS, 302.4; HFEC, 118.2; HFRS, 141.7 ± 15.3) (Fig 4.2). RS rats had a lower
cecal contents pH value compared to the EC rats (p<0.0001), and LF rats had a lower pH than
HF rats (p<0.0001). This resulted in a significant fat x diet interaction, with LFRS rats having the
lowest pH of cecal contents (LFEC, 8.41; LFRS, 6.67; HFEC 8.23; HFRS, 8.32 ± 0.08) (Fig 4.3).
STUDY 2
In the pre-treatment period, OVX rats consumed more energy (OVX, 2447; SH, 2122 ±
32.14 kJ, p<0.0001) and more food than sham rats (OVX, 748; SH, 649 ± 9.82 grams, p<0.0001)
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Fig 4.1. Average daily food intake for HF/LF study

Table 4.1. Measurements from HF/LF study according to Fat (low fat [LF] and high fat
[HF]) and Diet (energy control [EC] and resistant starch [RS]) as the independent variables
Dependent Variable

LFEC

LFRS

HFEC

HFRS

SEM

Fat

Starch

Interaction

Beginning BW (g)

248

248

248

248

3

NS

NS

NS

Final BW (g)

366

383

397

402

8

0.0027

NS

NS

Disemboweled BW (g)

351

357

383

387

6

0.0001

NS

NS

Full Cecum Weight (g)

3

13.9

2.9

3.5

0.3

0.0001

0.0001

0.0001

Empty Cecum Weight (g)

0.6

2

0.6

0.8

0.05

0.0001

0.0001

0.0001

Epididymal Fat (g)

4.3

4.4

6.1

6.3

0.3

0.0001

NS

NS

Abdominal Fat (g)

2.7

2.8

3.7

4.4

0.3

0.0001

NS

NS

Perirenal Fat (g)

1.3

1.2

1.6

1.9

0.1

0.0003

NS

NS

Total Fat Pads (g)

8.3

8.3

11.4

12.6

0.7

0.0001

NS

NS

2077

2142

2085

2017

56.3

NS

NS

NS

Energy Intake (kcal)
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Fig 4.2. Plasma PYY concentration for HF/LF study

Fig 4.3. pH of cecal contents for HF/LF study
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32.14 kJ, p<0.0001) and more food than sham rats (OVX, 748; SH, 649 ± 9.82 grams, p<0.0001)
(Table 3). Body weight change during the pre-treatment period was significantly greater for
OVX rats than sham rats (OVX, 112; SH, 44 ± 2.29 grams, p<0.0001) (Table 4.2). During the
treatment period, energy intake was higher in RS rats compared to EC rats (p<0.0029) (OVEC,
4640; OVRS, 4856; SHEC, 4473; SHRS, 4857 ± 93.83) (Table 4.3). Food intake was also higher
in RS rats compared to EC rats (p<0.0029) (OVEC, 1419; OVRS, 1485; SHEC, 1368; SHRS,
1485 ± 28.7) (Fig 4.4). Body weight was higher only in OVX rats relative to sham rats
(p<0.0001) (OVEC, 349; OVRS, 342; SHEC, 284; SHRS, 282 ± 5.6), and so was disemboweled
body weight (p<0.0001). But disemboweled body weight was also higher in EC rats compared to
RS rats (p<0.06) (OVEC, 332; OVRS, 320; SHEC, 268; SHRS, 260 ± 5.2) (Table 4.3). Full total
gastrointestinal weight (p<0.0001), full cecum weight (p<0.0001), and full small intestine weight
(p<0.0.0349) were higher in RS rats relative to EC rats (Table 4.3). Mesenteric fat (p<0.0016),
ovarian fat (p<0.0405), perirenal fat (p<0.0208), retroperitoneal fat (p<0.0112) (Table 4.3), and
the total fat pad weights (p<0.0065) (Fig 5) were all lower in the RS rats relative to EC rats.
Plasma PYY levels were higher in the sham group fed RS (OVEC, 42.4; OVRS, 34; SHEC,
34.7; SHRS, 53.3 ± 3.2). OVX rats fed RS, however, had lower total PYY levels (Fig 4.6). This
resulted in a significant diet x surgery interaction. Diet had no effect on plasma GLP-1 levels
(OVEC, 5.8; OVRS, 4.9; SHEC, 6.2; SHRS, 5.7 ± 0.5) (Fig 4.7).
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Table 4.2. Measurements according to surgery (ovariectomy [OVX] and sham [SH]) after 6
week recovery period and before diet treatments
Dependent Variable

OVX

SH

SEM

Surgery

Beginning BW (g)

208

197

1.8

0.0001

BW after 6 Weeks (g)

346

283

3.9

0.0001

Fat (g)

54.3

39.8

0.7

0.0001

Fat/BW (%)

16.8

16.3

0.2

NS

Energy Intake (kcal)

1452

1427

23

NS

Weight Gain (g)

116

46

2.3

0.0001

Energy efficiency (g/kcal)

8.0

3.3

0.2

0.0001

Fig 4.4. Cumulative food intake for OVX/SH study
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Table 4.3. Measurements for 13 week study with Diet (energy control [EC] and resistant starch
[RS]) and surgery (ovariectomy [OVX] and sham [SH]) as the independent variables
Dependent Variable

ECOV

RSOV

ECSH

RSSH

SEM

Diet

Surgery

Interaction

Beginning BW (g)

322

326

245

242

4

NS

0.0001

NS

Beginning Fat (g)

54.3

54.4

39.8

39.7

1

NS

0.0001

NS

Beginning Fat/BW (%)

16.8

16.7

16.3

16.4

0.3

NS

NS

NS

Disemboweled BW (g)

332

320

268

260

5

0.06

0.0001

NS

Full GI Tract (g)

17.3

22.3

16.0

20.3

0.9

0.001

0.08

NS

Full Small Intestine (g)

9.8

10.2

9.4

10.7

0.4

0.04

NS

NS

Full Large Intestine (g)

7.5

12.2

6.2

9.6

0.7

0.0001

0.006

NS

Mesenteric Fat (g)

3.1

2.5

2.8

2

0.2

0.0016

0.03

NS

Ovarian Fat (g)

5.1

4.2

4.5

3.4

0.4

0.04

NS

NS

Perirenal Fat (g)

1.9

1.4

1.4

1.1

0.2

0.2

0.02

NS

Retroperitineal Fat (g)

2.2

1.7

1.3

1.1

0.1

0.01

0.0001

NS

Total Fat Pads(g)

12.3

9.9

10

7.6

0.8

0.007

0.009

NS

Energy Intake (kcal)

4640

4856

4473

4856

94

0.003

NS

NS
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Fig 4.5. Total abdominal fat pad weights for OVX/SH study

Fig 4.6. Plasma PYY concentration for OVX/SH study

41

Fig 4.7. Plasma GLP-1 concentration for OVX/SH study
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CHAPTER 5
DISCUSSION
Dietary resistant starch is a fermentable fiber that resists digestion in the gut. As a
component of the diet, its indigestible quality results in dilution of the metabolizable energy of
the diet, fecal bulking comparable to non-fermentable fiber, and fermentation in the colon to
SCFAs with a subsequent increase in PYY and GLP-1 expression in the gut (Nugent, 2005;
Keenan et al., 2006; Zhou et al., 2006). Energy dilution has been considered a treatment
possibility for obesity if a person consumes a certain volume of food as opposed to a certain
amount of energy (Rolls et al., 1998; Willet, 1998), thus displacing extra calories with
indigestible matter (Howarth, Saltzman, & Roberts, 2001). The gut neuropeptides PYY and
GLP-1 have both been reported to decrease food intake (Batterham et al., 2002; Batterham et al.,
2003; Strader & Woods, 2005). It is through these mechanisms that RS is proposed to aid in
reduction of body fat and weight gain. RS has been reported to reduce fat pad weight (De
Deckere et al., 1993; Lerer-Metzger et al., 1996; Kabir et al., 1998a) and lower abdominal fat
(Keenan et al., 2006a).
In the first study we examined the effects of RS in a high fat diet on weight, body fat,
fermentation, and gut signaling. In the second study we examined the effects of RS in an
ovariectomized rat model of obesity on weight, body fat, fermentation, and gut signaling. RS has
been previously demonstrated to decrease body weight and adipose tissue (De Deckere et al.,
2003, Keenan et al., 2006a) and increase gene expression of PYY and proglucagon, the gene that
encodes GLP-1 (Zhou et al., 2006).
In the first study, we found that rats fed the HF diet ad libitum did have an increase in
body weight over the treatment period. RS, however, did not reduce body weight or body fat in
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either the HF or LF rats. Disemboweled body weight was higher in HF rats relative to LF rats.
Cumulative food intake was also higher for LF rats compared to HF rats to compensate for the
decreased energy density due to the lowered amount of fat in the diet. Energy intake remained
the same for all treatment groups. Epididymal, abdominal, perirenal, and total fat pads were
higher in HF rats compared to LF rats. However, RS was not effective in reducing body fat. This
is not consistent with the study performed by Keenan et al (2006a) when fed a LF diet.
Both full and empty cecum weights were, however, higher in RS rats compared to EC
rats. The presence of RS in the diet also lowered the pH of cecal contents in the LF diet, resulting
in a significant diet x surgery interaction. These results are consistent with previous studies
regarding the effects of RS on fermentation (Nugent, 2005; Keenan et al., 2006a), although RS
was not effective in lowering pH in the HF group. Plasma PYY levels were also found to be
higher in the RS rats, which has been attributed to the fermentation of RS in the colon (Keenan et
al., 2006a; Zhou et al., 2006).
In the second study, both OVX and sham rats were put on a control diet for six weeks to
allow OVX rats to gain weight. During this pre-treatment period, OVX consumed more energy
and food, and gained more weight than sham rats. After six weeks, the rats were put on their
respective diet treatments. During the treatment period, both energy and food intake were higher
in RS rats compared to EC rats. By the end of the study, body weight was still higher in OVX
rats relative to sham rats. RS rats did have lower disemboweled body weights compared to EC
rats, although this only approached statistical significance (p<0.06). However, mesenteric,
ovarian, perirenal, retroperitineal, and total fat pads were all lower in RS rats compared to EC
rats. Small intestine weight, cecum weight, and total gastrointestinal weight were all higher in
RS rats relative to EC rats. Lowered disemboweled body weight, lowered fat pads, and greater
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intestinal weights in RS rats were also seen in a previous study by Keenan et al (2006a). This
once again reinforces the fact that RS increases fermentation and lowers body fat in the
endocrine obese model and those fed a low-fat diet.
Unlike the previous study, plasma PYY levels were only increased in sham rats fed RS
and not OVX rats fed RS. The presence of RS also had no effect on GLP-1. Both Zhou et al and
Keenan et al reported an increase in GLP-1 and PYY levels, and increased proglucagon and
PYY gene expression, attributing these gut peptides as to at least one mechanism of body fat
reduction.
Both studies performed here were to examine the effects of RS on obese models. The rats
in the first study were fed a high fat diet to model a more “westernized diet” to induce obesity,
and the rats in the second study were ovariectomized to induce obesity. RS was not effective in
lowering either weight or body fat in the high fat diet or low fat diet. The effect of RS on a high
fat diet (44.8% of energy, 22% fat w/w) has not been tested before, but RS has been shown to
reduce body fat in a low fat diet (17.1% of energy, 7% fat w/w). We did not observe this even in
our low fat diet. A possibility for its ineffectiveness on the low fat diet in this study may be
attributed to the lowered amount of sucrose in the diet. In the study by Keenan et al (2006a) and
another by Shen et al (2008), 100g of sucrose/kg of diet was used, whereas only 50g of
sucrose/kg of diet was used in this study. This lowered amount may have affected the palatability
of the low fat diet, which is already low in fat, and rats may not have consumed enough RS to be
effective. We compared body weight, disemboweled body weight, and body fat between our rats
and Shen’s rats to evaluate how the difference in the amount of sugar effected these
measurements. Our rats and Shen’s rats were ordered from the same company, were the age and
type of rat, and arrived on the same day. Upon comparison, Shen’s rats had a greater body
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weight and disemboweled body weight for both the energy control and resistant starch diets
(Figures 5.1 and 5.2). Body fat was also higher in Shen’s rats relative to our rats (Figure 5.3).
Both our low fat diet and Shen’s diet had the same amount of fat, but Shen’s diet was prepared
with 100g sucrose and fed for only 65 days whereas ours was prepared with 50g of sucrose and
fed for 85 days. The combination of a low fat diet and a lowered amount of sugar may have
compromised food consumption, which ultimately could have affected RS consumption and
effectiveness or possible fat gain by EC rats.
In this study, we also noted that full and empty cecum weights were significantly lower in
the high fat diet than the low fat diet, and pH was significantly higher in the high fat diet
compared to the low fat diet. These results indicate that fermentation was eliminated with the
high fat diet. Dietary fat has previously been reported to reduce fermentation of fiber in

Fig 5.1. Body weight comparison of rats from Shen’s low fat diet with 100g of sucrose and our
low fat diet with 50g of sucrose
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Fig 5.2. Disemeboweled body weight comparison of rats from Shen’s low fat diet with 100g of
sucrose and our low fat diet with 50g of sucrose

Fig 5.3. Total fat comparison of rats from Shen’s low fat diet with 100g of sucrose and our low
fat diet with 50g of sucrose
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ruminants (Macleod & Buchanan Smith, 1972; Devendra & Lewis, 1974; Kowalczyk et al.,
1977). If fat can affect fiber fermentation, then the high fat diet used in this study may also be
blunting the fermentation of RS. Endogenous lipids have also been shown to complex with the
amylose chains in RS, which can disrupt RS formation (Eerlingen et al., 1994). If RS is not
formed, it is most likely being digested just as a starch, fermentation is not allowed to take place,
and the subsequent physiological effects of RS are being hindered.
In the second study, food and energy intake were higher in the RS rats compared to EC
rats. Interestingly though, EC rats still had a greater disemboweled body weight. This effect
appears to be driven by increased energy expenditure because energy intake was lower in EC
rats. In an unpublished study by Zhou et al (2008), mice fed an RS diet also had a higher
cumulative food intake and lower body fat, and with a reported lower respiratory exchange ratio
(RER). This method of measuring respiratory gases is an indication of fat burning. The lower
RER in RS mice compared to controls indicates greater fat burning. Higgins et al (2004) also
reported that replacement of 5.4% of total carbohydrate with RS significantly lowered the
respiratory quotient (RQ, a measurement of respiratory gases at the cellular level), and increased
fat oxidation. This moderate level of RS fed in humans also indicates greater fat burning. This
data suggests that in our studies RS does not decrease food intake, but its role is to increase fat
burning, which appears to promote its ability to reduce body weight and body fat.
Also in the second experiment, lowered disemboweled body weights, lowered fat pads,
and greater intestinal weights were all observed in the RS rats relative to EC rats, even though
there was no difference observed in GLP-1 between the diet treatments, and PYY appeared to be
effective only in sham rats fed RS. As stated before, it has been previously reported by Keenan et
48

al and Zhou et al that increased gene and protein levels of PYY and GLP-1 are associated with
consumption of RS. The fact that these two gut hormones were not associated with RS
consumption, but larger intestinal weights and reduced body fat were both still seen with RS
consumption suggests that RS may work through other hormones or another mechanism beyond
gut signaling. Previous work has presented gene array data demonstrating vast differences in
expression of the cecal cell genome in rats (Keenan et al., 2006a; Keenan et al., 2006b). Other
factors possibly involved include other gut hormones, neural, and immune factors.
In conclusion, the data from the current study suggests that RS is ineffective in reducing
body weight and body fat in rats when fed concomitantly with a high fat and low fat diet. These
results are contrary to previous reports of the association between RS consumption and reduced
body fat and body weight. It is possible that the high fat diet may blunt the effects of RS
fermentation. However, RS consumption did indicate that fermentation took place in rats fed the
low fat diet, although weight gain was too low in rats fed the low fat, RS diet due to due
decreased sucrose levels. In our second study, adding resistant starch to the diets of OVX rats
was effective in reducing accretion of abdominal body fat, even though the data did not support
it was done through gut signaling with PYY and GLP-1 as previously demonstrated. The
mechanism for this remains to be determined. However, this suggests that dietary resistant starch
may improve health by reducing body fat in postmenopausal women. Further research
investigating other possible means by which dietary resistant starch is effective in reducing body
weight and body fat is warranted.
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APPENDIX A:
STUDY PROTOCOL

PENNINGTON BIOMEDICAL RESEARCH
CENTER
INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE

GUIDELINES FOR SUBMISSION OF NEW PROTOCOL FORMS AND EXISTING PROTOCOL
AMENDMENTS FOR IACUC REVIEW

NEW PROTOCOL
A new protocol form must be filled out and submitted to the IACUC:

1) to receive approval to begin experiments/procedures using laboratory animals;

2) if there are changes in major operative procedures in previously approved protocol (the protocol is not
assigned a new number); or

3) if there are changes in species in a previously approved protocol (the protocol is not assigned a new
number).

PROTOCOL RENEWAL
As required by the Public Health Service Policy all protocols must be reviewed by the IACUC every three years. The
term renewal refers to IACUC action on a previously approved, but EXPIRING protocol. A new protocol form must
be submitted for a renewal at least every three years. Once renewed and approved by the IACUC, the protocol is
assigned a new number.
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PROTOCOL AMENDMENTS
A protocol may be amended if the original intent of the protocol does not change. A new protocol form is
generally not necessary; instead, simply submit a letter to the IACUC, citing the protocol number and title, and
outlining the change(s) requested. For questions concerning protocol amendments contact the IACUC chairman
or attending veterinarian. Examples of changes that may be made by a protocol amendment include:

1) addition of personnel to a protocol;
2) changes in drugs or drug dosages;
3) changes in animal numbers;
4) changes in group designations; or
5) changes in time length of experiments.
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INSTRUCTIONS FOR USING ANIMAL CARE AND USE PROTOCOL FORM:

1.

The most recent version of the IACUC Animal Care and Use Protocol form is available
on PINE under IACUC.

2.

Retrieve the form and save the file in another location on your computer or network
space: In the toolbar, select [File] and select [Save as…] . Give the file any name you
prefer.

3.

Gray boxes are shown for inserting responses to the questions. Text may be inserted
by placing the cursor at the return and typing or pasting text. Color has been used to
highlight especially important areas. The form will print in black if the usual LaserJet
printer is used.

4.

The IACUC encourages the use of tables, flow diagrams etc. for some responses.
However, Word® Forms does not allow these functions. Tables and diagrams may be
created and attached to the protocol where appropriate.

5.

After completing the form, you may want to remove excess hard returns between
sections in order to limit the finished protocol form to a minimum number of pages.

6.

Should you encounter any problems while using this form, please contact Nancy
Pease at ext. 3-2577.

7.

Submission instructions: Form must be typed. (Use additional sheets if necessary and
attach to this form). SUBMIT ORIGINAL to the IACUC Administrator‘s Office, Rm.
B1022.

8.

Delete the first two pages of instructions prior to saving your final version.

Pennington Biomedical Research Center
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PROTOCOL FOR ANIMAL CARE AND USE
SECTION 1: Investigators
Principal Investigator

Office Phone:

Home Phone:

Email Address

Roy J. Martin

578-2284

766-2684

martinrj@pbrc.edu

Co-Investigator:

Office Phone:

Home Phone:

Email Address

Jun Zhou

763-2531

924-6308

zhouj@pbrc.edu

SECTION 2. Project Title:

The role of PYY and GLP-1 in energy balance with resistant starch fed animals

SECTION 3. Funding Source: Is this protocol associated with a grant or contract?
Yes

No
NIH

Funding agency:
Grant or contract
title:
Pending

Dietary Resistant Starch: The role of PYY and GLP-1 in energy
balance

Funded

SECTION 4. Investigator’s Statement regarding the assurance for the Humane Care
and Use
of Vertebrate Animals.
By signing this form, I agree to abide by Pennington Biomedical Research Center’s Policy for
the Care and Use of Animals. This project will be in accordance with the NIH “Guide for the
Care and Use of Laboratory Animals” (except as explained in the accompanying protocol), and
the PBRC Animal Welfare Assurance on file with the U.S. Public Health Service. I further assure
the Committee that:
1) I will abide by all federal, state, and local laws and regulations governing the use of
animals in teaching and research.
2) The investigators and technicians are or will be adequately trained to perform the
research techniques required in these studies.
3) I will use the fewest number of animals required to produce the appropriate statistical
power for this study.
4) The research proposed herein is not unnecessarily duplicative of previously reported
65

research.
5) For those completing Section 14.2 and 14.3: I have reviewed the pertinent scientific
literature and the sources and/or databases as noted in Section 14, and have found
no valid alternative to any procedures described herein which may cause more than
momentary pain or distress, whether it is relieved or not.

Professor
Roy Martin
Type Name of Principal Investigator

Title/Rank

Date

Principal Investigator Signature

Jun Zhou

Post-Doc

Type Name of Co-Investigator

Title/Rank

Date

Co-Principal Investigator Signature

Animal housing and veterinary care must be coordinated with Comparative Biology.

Signature of Comparative Biology Representative (required)

SECTION 5. Animal Species:
Rat

Strain: C57BL/6J

Species:

Mouse

Sex:
Both

Male

Source:

Commercial Vendor

PBRC Breeding Colony

Species:

Mouse

Other

Sex:
Both

Male

Source:

Commercial Vendor

Female

Other
Either

Weight (or age for rodents): six weeks old

Rat
Female

Collaborator

Strain: Sprague Dawley

Either
Weight (or age for rodents): eight weeks old
PBRC Breeding Colony
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Collaborator

Species:

Mice

Rats

Other

Number of animals needed:
Year 1: →200

340

Year 2: →580
Year 3: →
TOTAL: →780

340

200

100

Maximum # needed at one time:

SECTION 6. Abstract Plan of Research/Teaching: In the space below, using nontechnical
terms provide a brief (1 – 2 paragraphs) layman’s description of the
project. Include the aim of the study and how this study may benefit human or animal
health or advance scientific understanding of biological processes.

Resistant starch is a dietary carbohydrate that resists digestion in the small intestine
and is fermented in the large intestine. Our preliminary studies showed that feeding
resistant starch significantly altered energy balance and decreased body fat in rodents.
Additionally, resistant starch fed rodents had higher gene expressions for peptide YY
(PYY) and proglucagon (a precursor of glucagon-like peptide-1, GLP-1) in the gut, and
higher serum levels of PYY and GLP-1. PYY and GLP-1 are satiety peptides secreted
from the gut. Administration of either PYY or GLP-1 reduces food intake. Thus, we
hypothesize that the decreased body fat is due to increased PYY and/or GLP-1
(PYY/GLP-1) in resistant starch fed animals. The hypothesis will be tested in three
specific aims. First, we will block PYY/GLP-1 action to determine if PYY and GLP-1 are
required for resistant starch to decrease body fat. This will be achieved by using
PYY/GLP-1 receptor antagonists or by using the PYY/GLP-1 receptors knock out mice.
Second, we will investigate if PYY/GLP-1 decrease body fat via visceral nerves or the
brain. The peripheral sites of action for PYY/GLP-1 will be tested by destroying visceral
afferent neurons to block signals to the brain. Finally, we will test if resistant starch
decreases body fat in robust obese animal models. A diet-induced obesity model and a
genetic obese model will be used to see if resistant starch can prevent obesity. These
experiments will reveal that PYY and GLP-1 are part of the mechanism of resistant
starch on reducing body fat. Thus, a simple dietary intervention can increase levels of
these peptides and reduce body fat naturally without surgery or pharmaceutical means.
This dietary approach is potentially of great therapeutic importance in the prevention of
human obesity.
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SECTION 7. Special Husbandry Requirements:
needs to be addressed by Comparative Biology?
Yes

Do your animals have special

No

If yes, please complete each section that is different from the standard of care for rodents. The
standard of care is: plastic shoebox, corn cob bedding, rodent chow, ≅21-22°C room
temperature, ≅55% humidity, and tap water.
TEMPERATURE
21-22°C room
RANGE:
HUMIDITY:
55 (%)
temperature
LIGHT CYCLE (hours light/hours dark)

12/12
Type: 1) Shoe boxes

for breeding mice

CAGING

Type: corncob and
BEDDING/LITTER

nesting material

CAGING

Type: 2) appropriate
SS hanging wire cages
for experimental mice
and rats
Type: pan liners and

BEDDING/LITTER

weigh backs

WATER

Sterile:
N

Y

Size:
single /multi

Filter tops required?

Y

N

Y

N

Autoclaved?
Y

N

Changes/week: 3

Size: Single

Filter tops required?

Autoclaved?

Changes/week: 1

Y
De-ionized:
N

N
Y

By investigator only*
Acidified:
N

Y

Tap:
N

Y

* weigh backs will be changed 3 to 7 times per week by investigator
when measuring spillage. Pan liners will be changed 1 time per week
Other: by investigator
Special Feeding Requirements:
DIET

Investigator will mix custom diets (see table below) and feed
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experimental animals
3-7 times per week.
Breeder mice will be provided breeder chow by DCB.
IF USING WIRE BOTTOM CAGES, PLEASE JUSTIFY:
We will measure food intake in our animals. Hanging wire cages are required so that we can accurately
account for food spillage. As experiment period could last as long as 12 weeks, a PVC tube will be placed
in each mouse cage to reduce the stress caused by wire cage. Breeder pairs will be multi-housed in
shoeboxes. Prior to due date, males will be removed and either place with an available female or single
housed in shoe boxes. Females will be singled housed with neonates until weaned. Weanlings will remain
in shoe boxes until placed in experiments.
OTHER SPECIAL NEEDS:
Table 1. Experimental Diet Composition
Control
(g/kg)

30% RS(g/kg)

High Fat
(g/kg)

Casein

200.0

200.0

200.0

200.0

Sucrose

100.0

100.0

50.0

50.0

Ingredient

Control

High Fat 27% RS
(g/kg)

Cornstarch - Amioca®
(100% amylopectin)

424.5

Cornstarch - Hi-Maize® (high
amylose)

384.5

530.7

480.7

Cellulose fiber

156.2

50.0

96.2

Soybean oil

70.0

70.0

100.0

100.0

120.0

120.0

Vegetable shortening
Mineral Mix (AIN-93G)

35.0

35.0

35.0

35.0

Vitamin Mix (AIN-93)

10.0

10.0

10.0

10.0

Choline Chloride

1.3

1.3

1.3

1.3

L-Cystine

3.0

3.0

3.0

3.0

Total
Protein

(3.27 kcal/g)

(3.27 kcal/g)

(4.2 kcal/g)

(4.2 kcal/g)

22.2% kcal

22.2% kcal

17.2% kcal

17.2% kcal
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Carbohydrates

59.7% kcal

59.7% kcal

38.1.7% kcal

38.1% kcal

Fat

18.1% kcal

18.1% kcal

44.8% kcal

44.8% kcal

SECTION 8. Hazardous Materials: Will zoonotic/recombinant agents or hazardous
chemical agents be PRESENT IN THE ANIMAL ROOM?
YES

NO

If “yes” complete the appropriate section(s) below.
8.1

Zoonotic/Recombinant Agents:
If zoonotic (infectious to humans)
recombinant agents will be used, this protocol request must be submitted to
LSU Institutional Biological Recombinant DNA Safety (IBRDS) Committee
approval PRIOR TO CONSIDERATION by the IACUC. Submit copy of
IBRDS approval letter to the IACUC Administrator with the animal protocol.

or
the
for
the

List
Agent(s):

IBRDS Approval Date:

8.2

PBRC Safety Officer:

Hazardous Chemicals: If hazardous chemical are to be used in the animal
room, submit the proposal with Appendix A completed, to the Biosafety
Committee for prior approval. SOPs for some commonly used materials are
available on PINE.

List
Chemical(s):

Biosafety Committee Approval Date:

8.3

Radioisotopes: Use of radioisotopes is not allowed in Comparative Biology.
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Will radioisotopes be used in
animals?

YES

NO

List Radioisotopes:
Are you certified by the Radiation Safety
Committee?

YES

NO

Where (Room #’s) will radioisotopes be used in animal
experiments?
YES

Is this a terminal experiment?

NO

If you have any questions regarding approval of the use of zoonotic/recombinant
agents, hazardous chemicals, or radioisotopes see the PBRC Safety Office @
3-2667.

SECTION 9. Type of Project: (check the appropriate box)
TYPE A - Pain or distress will not be induced; animals will only be used for
injections, collections, or procedures causing nothing more than minor
discomfort; or will be humanely euthanized prior to induction of pain or distress.
TYPE B - Pain or distress will be relieved by appropriate therapy.
TYPE C - Drug intervention for pain or distress would interfere with the protocol.
Specific scientific justification MUST be provided below for Type C protocols.
Justification for Type C protocol:
none

SECTION 10. Summary of Procedures: Answer each of the following. If a section is
not applicable, indicate so by “N/A”. Your target audience is a faculty member from a
discipline unrelated to yours.
10.1. Rationale: Explain your rationale for animal use. Briefly explain why should this
study be done and what hypothesis/es will be tested?
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Resistant starch has been used as a dietary carbohydrate in humans. However, the
effects of reducing body fat by resistant starch are equivocal due to the complexity of
human dietary studies. Using rodents to study the effects of resistant starch will allow
control of the genetic verities, daily activity and dietary components. Using knock out
mice could allow us to study the mechanism of resistant starch on reducing body fat.
The results of our study will provide the important mechanistic information on how
resistant starch reduces body fat. More specifically, if resistant starch reduce body fat
through increase in secretion of PYY and GLP-1 in the gut.

10.2.

Species Selection: How and/or why you selected the animal species indicated?
Mice and rats are selected because these animals are commonly used for mechanistic studies on
body weight regulation and energy balance.

10.3. Experimental Design: Provide a concise description of the proposed use of animals.
This description should allow the IACUC to understand the experimental course of each
group of animals from its entry into, until the endpoint of the experiment. A flow chart
(timeline/sequence), diagram, and/or a table (see note below) indicating animal numbers
and group assignments are STRONGLY recommended to help the IACUC understand
what is proposed. Include experimental procedures and any physical, chemical, or
biological agents (name, dose, volume, route, and frequency) that may be
administered. Details of specific nonsurgical and surgical procedures should be provided
in Sections 10.5 and 10.6 respectively. Form Note: Due to the difficulty of inserting
tables and flow charts/diagrams directly into the form consider creating these in Word
and attaching them to the end of protocol.
.
Animal number and timeline for proposed studies is listed below.
Experiment
Expt. 1.
Expt. 2
Expt. 3
Expt. 4
Expt. 5
Breeding mice
for Expt. 6
Breeding mice
for Expt. 7
Expt. 6
weeks
Expt. 7
weeks

Animal number
140 SD rats
100 SD rats
100 SD rats
80 mice
100 mice

Year
1
1
1
2
1

Length
10 days
Six weeks
Six weeks
12 weeks
12 weeks

100 mice

1

100 mice
200 mice

2
2

12

200 mice

2

12
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Experiment 1. Determine the timing of sample collection.
We will feed two groups of SD male rats with either control or resistant starch diet
for ten days. At the end of Day 10, the rats will be killed by decapitation at 0, 2, 4, 8, 12,
16, and 20 hours after the beginning of the dark cycle (ten rats for each time points for
each group). The blood, brain and tissues from the gut will be collected from each rat.
PYY/GLP-1 expression levels in the blood and gut will be measured for each rat.
Experiment 2. Will injecting both Y2R and GLP-1R antagonists simultaneously in
rats block the action of both PYY and GLP-1?
BIIE0246 is a well-established PYY receptor antagonist and des-His1 Glu9exendin-4 is a GLP-1R antagonist. Both antagonists have been used safely in mice and
rats at the dosage described below for PYY and GLP-1 functional studies. (1-7)
Protocol: One hundred male SD rats will be divided into four weight matched groups:
(1) saline, (2) BIIE0246 (2.0ug/g body weight, dissolved in 10% DMSO of
saline i.p.), (3) des-His1 Glu9-exendin-4 (0.23ug/g body weight, dissolved in
saline, i.p.) and (4) BIIE0246 plus des-His1 Glu9-exendin-4. The injection
dosages and route will be the same as group (2) and (3). The injection volume
for all groups will be 0.2ml/100g body weight and the injection frequency will
be once per day. Each injection group will be subdivided into resistant starch
fed group and control diet fed group (12 rats for each sub-group). Food intake
and body weight for each rat will be measured three times per week. At the
Week 5 after the first injection, all rats will be subjected to measured body fat
by NMR. The experiment will be terminated six weeks after the start of
injections. All rats will be killed by decapitation and their blood, gut, fat
depots will be collected.
Experiment 3. Test if PYY & GLP-1 decrease body fat via visceral nerves or the
brain.
Visceral afferent nerves from the gastrointestinal tract carry important signals to the
brain to control energy balance and body fat. Thus, we will treat rats with capsaicin to
destroy visceral afferent neuron and determine if the effects of resistant starch can be
abolished. Capsaicin has been used traditionally in study the involvement of visceral
sensory neurons (1, 8-10).
Protocol: One hundred male SD rats, weighing 150-180g, will be fed the control diet a
week before sub-grouped into capsaicin or vehicle treatment. Capsaicin-treatment
consists of 3 injections of progressively increasing doses over a period of 3 days,
each under gaseous anesthesia. Rats will be anesthetized with isoflurane and
doses of 12.5, 30, and 75 mg/kg of capsaicin will be injected ip. The first and
second injections typically result in temporary respiratory arrest, but breathing
will restart spontaneously or with the help of gentle chest massage. The entire
procedure is carried out under deep Isoflurane anesthesia. Ten minutes after
resumption of spontaneous breathing, anesthesia is discontinued and animals
allowed to recover. At the highest dose on the third day, there is usually no
respiratory arrest. Capsaicin will be dissolved in 10% ethanol/10% Tween 80 and
sterile saline, and delivered at 0.6 ml/100g for the highest dose. For control
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treatment, only the vehicle is injected. Two days after the last capsaicin or
vehicle treatment, a CCK feeding suppression test will be conducted to confirm
that capsaicin-sensitive visceral afferents have been destroyed by capsaicin
treatment. One day after the last CCK feeding suppression test, both vehicle
treated and capsaicin treated rats will be stratified by weight and assigned to
either the control diet, or the resistant starch diet for a six-week study. Body
weight and food intake will be measured three times per week. Four days before
the end of the study, gut transit time will be measured. At the end of the study,
the all rats will be killed by decapitation. The blood, fat depots, gut and brain will
be collected.
CCK feeding suppression test to confirm destroying capsaicin sensitive visceral
afferents
CCK suppresses food intake via visceral afferents. Thus, administration of
exogenous CCK will decrease food intake in control rats but not in capsaicin
treated rats. All rats will be fasted overnight. In the morning, CCK-8 (6ug/kg
body weight, dissolved in saline) or saline will be injected (i.p. 0.2ml/100g body
weight) into rats 30 minutes before feeding. One-hour food intake will be
measured for all rats. Half the rats of each treatment group (capsaicin or vehicle)
will receive CCK first and the other half will receive saline first, with tests 3 days
apart. Saline treatment will be used to measure normal food intake after an
overnight fast. CCK treatment should not decrease food intake in capsaicin treated
rats but should decrease more than 50% food intake in control rats. It there are
problems with CCK feeding suppression test, a sucrose solutions test will be used
as an alternative to confirm the destroying capsaicin sensitive visceral afferents.
A sucrose solution test to confirm the destroying capsaicin sensitive visceral
afferents(9)
Three days before the first exposure to sucrose, all rats will be offered daily
the 10% sucrose solution and allowed to lick for 10 seconds (<0.2ml). The
purpose of this training is to eliminate any neophobia toward the new food and
source but without allowing significant ingestion and its metabolic consequences.
By the fourth day, all rats immediately approached the spout and stared drinking.
The 10% test sucrose solution will be given in the morning between 8:30 and
11:00am in the bottle attached to the cage front. Intake levels for each rats will be
measured at 30 minutes and 60 minutes after offering the test sucrose solution.
Capsaicin treated rats should over consumption sucrose solution when compared
with controls.
Measurement of gut transit time(11, 12):
Each rat will be fed a bolus (2.5 g) of the appropriate experimental diet mixed
with glass beads (10 mg; diameter range 150-170um) at midnight. The rats will be
fasted (with free access to water) for 12 h before feeding the boli and all the boli
should be eaten completely. One hour later, rats will be given free access to food
again. Six hours after feeding the boli, fecal samples will be collected in glass
scintillation vials every 2 h up to 30 h after feeding and then every 6 h up to 48 h
after feeding. The gut transit time will be measured by counting the rate of glass
beads in the fecal sample.
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Experiment 4: Determine if resistant starch decreases body fat in a genetically obese mice
model

Intracerebroventricular injection of PYY or GLP-1 have decreased food intake in
lean and obese mice and their action is additive. Therefore we will determine if the
increased plasma levels of both PYY and GLP-1 in resistant starch fed mice are sufficient
to reduce body fat in ob/ob mice.
Protocol: Forty ob/ob (B6.V-Lepob/J) mice and forty of their lean (Lepob heterozygote)
littermates will be obtained from Jackson Lab and fed the resistant starch or
control diet for 12 weeks. Body weight and food intake will be measured three
times per week. Body fat will be measured at the week 0, 6, 11, when diet
treatment starts. At the end of 12 weeks, all mice will be decapitated and blood,
fat depots will be collected.
Experiment 5: Test if resistant starch decreases body fat in a diet induced obesity
mice model
C57BL/6J mice is susceptible to long-term high fat induced obesity. Furthermore, it
has been shown that injections of PYY and GLP-1 reduce food intake in this model of
obesity.
Protocol: one hundred male C57BL/6J mice will be divided into four groups and fed one
of following four diets. 1) Control diet, 2) resistant starch diet, 3) high fat control
diet , and 4) high fat resistant starch diet for 12 weeks. Body weight and food
intake will be measured three times per week. Body fat will be measured at the
week 0, 6, 11, when diet treatment starts. At the end of 12 weeks, all mice will be
decapitated and blood, fat depots will be collected.
Experiment 6: and 7 will determine if PYY/GLP-1 receptors are required for resistant
starch to decrease body fat. We will use Y2R knock out mice and GLP-1R knock out
mice to test our hypothesis. GLP-1R knock out mice are currently available in PBRC
comparative biology facility and we have obtained the permission to breed them from Dr.
Drucker. The Y2R knock out mice will be obtained from Dr. Herbert Herzog. As Y2R
knock out and GLP-1R knock out mice are homozygoteous, all progeny will be used to
replenish the breeding colony or the experiments. . However, we will genotyping retired
breeding mice to confirm the correct genotype. We will also breeding C57Bl/6J mice at
the same condition and use these mice as inbreed control for the experiment 6: and 7.
Breeding strategy.
Initial breeding will be set up with one male for 3 females in shoebox cages.
Once pregnancy is evident, female mice will be are single housed in shoe box cages with
corncob bedding and nesting material until pups are weaned at 21 days. Male and
female progeny mice will be used to replenish the breeding colony. We expect 6 to 10
mice per litter, thus allowing for 2 breedings of Generation I to produce a minimum of
18 females and 6 males. The synchronized timed breeding of these progeny should
produce adequate numbers of each type for experiments 6 and 7. If enough Generation
III progeny are not produced for experiments 6 and 7, then a second breeding of
Generation II will be initiated. Both male and female mice will be used in these
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experiments to limit the time needed achieve adequate numbers for all experiments. A
small number of the unneeded weanlings will be genotyped to determine if cross
breeding to produce Y2R-/- / GLP-1R-/- double knockout mice is possible. Any correct
genotyped mice will be held for cross breeding. A separate protocol would be written
for this.

Figure: Breeding strategy for each breeding set:

Male

Female

Timed breeding for experiments 6 and 7

Generation

I: Initial breeding group 3 females / one male

Generation IIa: First breeding -groups set up with all progeny
IIb: Second breeding -groups set up with all progeny
Generation III: breeding from IIa and IIb progeny timed to coincide

Number of animals: 200
100 C57Bl/6J controls: 2 breeding sets (to produce 300 male or female for Expt.
6, 7)
50 Y2R-/- knock out: 1 breeding set (to produce 150 male or female for Expt. 6 )
76

50 GLP-1R-/- knock out: 1 breeding set (to produce 150 male or female for Expt 7)
Retired breeders and extra weanlings will be used to determine optimum dosages
and for genotyping

Experiment 6 Will injecting the GLP-1R antagonist into Y2R null mice block the
action of both GLP-1 and
Experiment 6
PYY?
Saline

Control diet

100 C57Bl/6J
Resistant starch diet
Protocol: Y2R null mice and
their wild type littermates
Control diet
will be obtained from Dr.
Resistant starch diet
GLP-R antagonist
Herbert Herzog. Forty Y2R
null mice and forty wild
type littermates (6-week old
Saline
Control diet
males and females) will
Resistant starch diet
100 Y2R null
have free access to the
Control diet
control diet and water for a
week. Body weight and food
Resistant starch diet
GLP-R antagonist
intake will be measured
daily. At the end of one
week of baseline measurements, the mice in each genotype group will be divided into
two subgroups: Saline-injected and GLP-1R antagonist-injected (des-His1 Glu9exendin-4, 2.33ug/0.1ml/10g body weight, dissolved in saline). The injection (i.p.) will
be performed daily. Each injection group will be further subdivided into two subgroups:
one subgroup will be fed the resistant starch diet and the other group will remain on the
control diet. Body weight and food intake will be measured three times per week and
body fat will be measured every ten days. The experiment will end one week after the
body fat becomes significantly lower in the saline-injected wild type mice fed resistant
starch as compared with the same genotype mice but fed the control diet. This
significantly lower body fat in resistant starch fed mice will occurred within 12 weeks
from our previous experiment results. At the end of study, all mice will be killed by
decapitation and their blood, brain, fat depots, and gut will be collected.

Experiment 7: Will injecting
the Y2R antagonist into the
GLP-1R null mice block the
action of both PYY and GLP-1?

Experiment 7
Control diet
100 C57Bl/6J

Saline

Resistant starch diet
Control diet

Y2R antagonist

Resistant starch diet
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Control diet
100 GLP-1R null

Saline

Resistant starch diet
Control diet

Y2R antagonist

Resistant starch diet

Protocol: The same protocol will be used as in experiment 6, except we will use forty
GLP-1R null mice and forty wild type littermates (6-week old males and females), and
the antagonist for Y2R (BIIE0246, 20ug/0.1ml/10g body weight, dissolved in 10%
DMSO of saline, i.p.) will be injected into these mice. The GLP-1R knockout mice and
their wild type littermates will be obtained from Dr. J. Drucker.
10.4. Justification of Animal Numbers: Justify the method used to determine the
number of animals used for the experiments described in Section 10.3. This
could include statistical power analysis, numbers necessary as a continual
source of tissue harvest for ongoing work, prior experience with similar
experiments or a limited number for pilot or feasibility studies. Numbers
described here should coincide with Sections 5 and 10.3.
The number of animals used in each experiment is based on a power analysis and on the
investigator’s experience. The standard deviation of the different measurements
determines the number of animals to be used in the above experiments and the standard
deviation varies with different measurements. To provide adequate tissue and blood
samples for measurements of food intake, blood hormone, and gut peptide/brain
neuropeptide gene expression, 10-25 rats and 20 to 25 mice are required. Additionally,
the number of animals needed may be reduced as adequate information from preliminary
experiments and breeding numbers are achieved.
10.5. Non-Surgical Procedures: List and describe each non-surgical procedure to
which any animal or group of animals may be subjected. Indicate, where
appropriate, analgesic, anesthetic, and/or tranquilizing agents that will be used to
minimize discomfort and pain.
1. Food intake and body weight measurements: During the defined experimental
periods within the study protocol, food intakes and body weight will be measured either
daily or every 2-3 days. Food and tap water will be provided ad libitum. Food cups with
experimental diets (table 1) will be prepared and provided by investigator. We
anticipate very little stress under these situations.

2. Over night fasting: For CCK feeding suppression and gut transit time, the rats will be
fasted overnight. Food cups will be removed at the start of the dark cycle and returned
on the following morning and water will be available at all times.

3. Measurement of gut transit time: Each rat will be placed in a metabolism cage with
free access to water and fasted for 12 hours before feeding a bolus (2.5 g) of the
appropriate experimental diet mixed with glass beads (10 mg; diameter range 15078

170um). After one hour and rats will be given free access to food again and will remain
in the metabolism cages for 48 h after feeding for collection of fecal samples. The size of
the glass beads should not interfere with digestion or cause stress. The rats will be
returned to their normal cages after the procedure.

4. Intraperitoneal injection:
Y2R/GLP-1R antagonists, saline, and CCK will be intraperitoneally injected into animals.
The injection will be carried by an experienced investigator to reduce the transitional
discomfort of each animal.

5. Visceral afferent lesion by capsaicin injections: The neurotoxin capsaicin will be i.p.
injected to rats in experiment 3 to lesion their visceral afferent. The entire procedure is
carried out under deep Isoflurane anesthesia (induction concentration of 4 -5%
isoflurane with 20% oxygen and a 1 L/min flow rate, maintenance concentration of 2%
isoflurane). The capsaicin will be injected consecutively for three days with increased
dosages as described in Experiment 3. The first and second injections typically result in
temporary respiratory arrest, but breathing will restart spontaneously or with the help
of gentle chest massage. Ten minutes after resumption of spontaneous breathing,
anesthesia is discontinued and animal is allowed to recover.

6. Body fat measurement by NMR: We observed difference in body weight for resistant
starch fed and control fed groups in mice studies. Body fat will be measured by NMR
for all animals before the end of experiments. The mice will be handled daily before
this measurement to reduce stress effects during this procedure. We anticipate little
stress effects under such situation.

7. Breeding, Weaning and genotyping: One male and 3 females will be initially obtained
for each of the three homozygote mouse models (Y2R -/-, GLP-1R -/-, and C57Bl/6 +/+
control). We anticipate 2 breedings for the initial females and 1 second generation
intercross breeding to produce the number of animals required for preliminary testing
and experiments. Breeding animals will be placed in shoe box cages with corncob
bedding and nesting material in each cage. One male will be placed with up to three
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females per shoe box. Once a female is visibly pregnant, she will be single housed until
after all pups are weaned. Pups will be weaned at 21 days. Male and females will
separated and multi-housed in shoeboxes until reaching maturity (six weeks of age). At
that time they will either be placed in shoeboxes for intercross breeding, or placed in
stainless steel cages for experimental procedures. The initial breeding mice will be earpunched for identification and tail-clipped for genotyping. For tail tip collection for
genotyping, the mouse is restrained briefly and 2-3 mm of the distal tip of the tail is
rapidly excised with a sterile scalpel blade or sharp scissors. Before the mouse is
returned to the cage, the end of tail is touched to a silver nitrate cauterizing stick to
minimize bleeding and dipped in bupivicaine/lidocaine mixture as a local anesthetic.

10.6. Surgical Procedures:
Does this protocol contain survival surgical procedures?
YES (Complete 10.6.a-h)
NO
Does this protocol contain non-survival surgical procedures?
YES (Complete 10.6.a-f)
NO
Does this protocol contain multiple major survival surgeries to occur on an
individual animal?
YES (Must provide scientific justification
below.)
NO

Justification for multiple major surgical procedures:
10.6.a Surgical description: Describe in detail each surgical procedure.
Include surgical prep of animal, aseptic techniques, surgical approach, wound
closure and suture removal plan.

10.6.b. Location: Where will surgeries be performed?

10.6.c. Personnel: List all personnel involved in the appropriate row below.
Name

Lab
Phone

Surgery
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Home
Phone

Email

Anesthesia

Post-op care

10.6.d. Anesthesia: Complete for each anesthetic drug used.
Drug

Dose

Isoflurane

4-5%

Freq

1ml/min

Route of
Administration

Inhalation

10.6.e. Anesthetic monitoring: Check method(s) used for anesthetic
monitoring.
Palpebral reflex

Toe pinch withdrawal

Other
Frequency of
monitoring:

Procedure last about 10 minutes, we will constant monitoring
animals for 30 minutes after procedure started.

10.6.f. Paralytic agents: Will paralytics be used?
Yes If “yes” complete table below.
No
Agent

Dose

Method of Monitoring

10.6.g. Postoperative care: Describe postoperative monitoring and care
provided.
First
24 hours:
Second
24 hours:
Thereafter:
10.6.h. Postoperative analgesia: Investigators should assume that procedures

that cause pain in humans also cause pain in animals. Please complete table
below for analgesics.
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Drug
bupivicaine/lidocaine mixture

10.7

Dose
once

Route of
Administration
At site of tail clip

Freq/Duration
Locally

Euthanasia: What method or agent will be used to euthanize the animals?
Include dosage and route of administration. Also include a secondary method of
euthanasia to ensure death. Methods of euthanasia that are not considered
“acceptable” by the latest version of the AVMA Panel on Euthanasia require
scientific justification.
CO2 for retired breeders and incorrect genotyped weanlings. Decapitation
for experimental mice and rats in order to collect brain samples for
measurement of neuropeptides NPY and AGRP as well as their gene
transcription. Anesthesia interferes with these brain neuropeptides
measurements.
Method:
Drug:
Route of
administration:
Secondary method:
Who will perform
euthanasia?

Jun Zhou, Kathleen L McCutcheon

Justification for use of “conditionally acceptable” methods of euthanasia:
Animals will be euthanized at the end of the experiments by rapid decapitation. Due to
the nature of the biochemical measurements to be performed, euthanasia of some
animals must be carried out by decapitation without anesthesia. Stress and anesthesia
interferes with the brain neuropeptides measurements of neuropeptides NPY and AGRP
as well as their gene transcription. Individuals who have had previous training and
experience with the procedure will carry out decapitation in order to minimize stress.
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SECTION 11. Procedure Checklist: Check “Yes” or “No” to each of the following
questions. The information you provide in this section is very important in highlighting
specific points of your study that are important considerations for the IACUC in their
review process.

11.1.

Restraint: Will animals be restrained? (Restraint refers to immobilization or
other restrictions to normal movement beyond momentary holding for injections,
etc.)
YES

NO

Body fat will be measured by NMR without anesthesia

If “yes” how?

How long?

For tail tip collection for genotyping, the mouse is restrained briefly and
2-3 mm of the distal tip of the tail is rapidly excised with a sterile scalpel
blade or sharp scissors

Less than 1 minute

Describe monitoring during restraint
period.

Who is responsible?

Respiratory rate

Jun Zhou, Kathleen McCutcheon

11.2. Animal Transport: Will it be necessary to take live animals outside of
Comparative Biology? If animals are removed from Comparative Biology they
cannot return.
YES

NO

If “yes”, justify and answer questions below.
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Justification:

List rooms where animals will be
taken:

How long will they be kept in laboratory? Animals cannot be held outside of
Comparative
Biology for greater than 12 hours without IACUC
approval.
List procedures performed on
animals:

11.3. Food and water restriction: Will food and/or water be withheld? (Please refer
to the IACUC Policy Statement on food and water restriction posted on PINE
under IACUC)
YES

NO

If “yes” for how
long?

Overnight – up to 12 hours

11.4. Blood collection: Will blood be collected?*
YES

NO

If “yes”:
How often?

Once , at the end of experiment after decapitation

What is the maximum number of collections on a given
animal?
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1

What is the maximum volume per collection?

All

What collection technique will be used?

Truck blood
Jun Zhou and
Kathleen L
McCutcheon

Who will perform collection?

* Guidelines for blood collection. The single blood collection limit is 10% of the
animal’s estimated blood volume (6ml/100g bw), which for a mouse is 60 µl/10g
of body weight and for a rat is 600 µl/100g of body weight. The repeat bloodsampling limit is the volume equal to 1.5% of the animal’s body weight per 2
weeks. Collections exceeding these limits require scientific justification.

11.5. Animal Breeding: Will breeding of animals be part of this protocol?
YES

NO

If “yes”:
What breeding scheme (pairs, trios, harem) will be
used?
Who will be responsible for breeding
animals?

Pair, trio and harem

Jun Zhou and Kathleen L McCutcheon

Who will be responsible for maintaining records and reporting use of animals
generated
in breeding colony to Comparative Biology
office?

Kathleen L McCutcheon and Jun
Zhou

What will the disposition of excess offspring or animals of incorrect genotype?
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Culled – CO2 if necessary. Excess mice will be used to determine dosage for
experiments

11.6. Genotyping: Will collection of tail tips or other tissue be required for
genotyping?
YES

NO

If “yes” describe technique and what anesthetics/analgesics will be used.
Mice will be restrained briefly and 2-3 mm of the distal tip of the tail is rapidly excised
with a sterile scalpel blade or sharp scissors. Before the mouse is returned to the cage,
the end of tail is touched to a silver nitrate cauterizing stick to minimize bleeding and
dipped in bupivicaine/lidocaine mixture as a local anesthetic.

11.7. Identification: Will individual animals be identified?
YES

NO

If “yes” how? (e.g. ear punch, ear tag, tattoos)
Breeder mice will be ear punched for identification. Weanlings will be ear punched at
weaning before genotyping

11.8. Adverse effects: Do you anticipate any adverse effects of the experimental
procedures on the animals?
YES

NO

If “yes”, list the possible effects (e.g., pain, discomfort, % weight loss, maximum
tumor size, fever, minimum packed cell volume, etc) and how they will be
monitored and addressed.
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•
•
•
•

Minimum weight loss due to overnight fasting.
Prolonged housing in stainless steel cage, a PVC tube will be provided for resting
surface and animals will be monitored when they are weighted.
Transit pain due to tail tips and intraperitoneal injection
Temporary respiratory arrest due to capsaicin injection. The breathing will
restart spontaneously or with the help of gentle chest massage. The entire
procedure is carried out under deep Isoflurane anesthesia. Ten minutes after
resumption of spontaneous breathing, anesthesia is discontinued and animals
are allowed to recover.

11.9. Death as an endpoint: Is death an endpoint in your experimental procedure?
Note: Death as an endpoint refers to experiments in which animals die as a direct
result of the experimental manipulation, not due to euthanasia at the end of a
study, e.g. acute toxicity testing, assessment of virulence of pathogens,
neutralization tests for toxins.
YES

NO

If “yes” provide scientific justification.

11.10. Emergency treatments: Are there emergency treatments by the Comparative
Biology veterinary staff that would not be allowed?
YES

NO

If “yes”, list treatments not allowed.
Contact investigators. Antibiotics, stress, and some medications will interfere with
experiments

11.11. Antibody production: Will animals be used for antibody production?
YES

NO
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If “yes”, list adjuvants to be used.

For use of Complete Freund’s Adjuvant provide scientific justification.

11.12. Exotic species: Are you using wild or exotic species for which permits are
necessary?
YES

NO

ATTACH COPY of permits. (Permits are required for protocol approval.)

SECTION 12.

Animal Management:

Check all applicable below:
CARE OF SICK ANIMALS

DISPOSAL OF DEAD ANIMALS

Call Investigator

Call Investigator

Clinician to Treat

Necropsy

Euthanasia

Disposal
List any special requirements for disposal?

SECTION 13. Disposition of Animals: (What will be done with animals at the
conclusion of the project? Check appropriate boxes.)

Animals will be euthanized.
Animals may or will be TRANSFERRED to another IACUC-approved protocol(s).
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Protocol Number:
Appropriate transfer forms must be completed and submitted to the Comparative Biology Office
when animals are transferred.

SECTION 14. Narrative Statements: Federal regulations mandate that you provide a
written narrative statement regarding whether the experiments described are
unnecessarily duplicative, and whether you have considered alternatives for those
procedures causing pain and distress.
14.1. Provide a narrative statement in the box below indicating that the proposed
experiments do not unnecessarily duplicate previous experiments. In this
statement, include sources used to make such a determination (e.g., Databases,
workshops, expertise in the field, etc).
After search electronic database, we confirm that the proposed studies are novel and will
not unnecessarily duplicate previous experiments.
If your source is an electronic database(s), complete the following boxes.
Date Search Completed:

04-01-2006

Database(s) Searched:

Medline

Keywords:

Resistant starch, PYY, GLP-1, knock out, receptor

Years covered in search:

1966-present

For Type B or C protocols answer 14.2 and 14.3 if you indicated Type B or C in Section
8.
14.2. Provide a narrative statement, in the box below, indicating whether or not you
have considered alternatives to procedures producing more than momentary or
slight pain or distress. Indicate what those alternatives were and why they are
not appropriate.
We have considered alternative procedures, but none that are appropriate for test our
hypothesis.
14.3

List the sources used to make the determination in 14.2. If your source is an
electronic database complete the boxes below.
Sources: Electronic database
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Date Search Completed: 04-01-2006
Database(s) Searched:

Medline

Keywords:

Resistant starch, PYY, GLP-1, knock out, receptor

Years covered in
search:

1966-present

SECTION 15. Investigator Training: In accordance with IACUC policy, all personnel
conducting animal-based research must attend a Comparative Biology/IACUC Orientation
Course. The principle investigator is responsible for training for skills specific to their research
project. Indicate individual responsible for this training below.
List all persons involved in animal care and use for this study below.
Training and
If no, who will do
Experience?
training?
Name
Jun Zhou

Kathleen L McCutcheon
Anne Raggio

Y

N

Y

N

Y

N

NOTE: All personnel must complete Comparative Biology’s training course in order to
have access to Comparative Biology.
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APPENDIX B:
ABBREVIATIONS
AIN-93G

American Institute of Nutrition- 93 Growing diet

BMI

Body mass index

CVD

Cardiovascular disease

EC

Energy control

GIP

Gastric inhibitory peptide

GLP-1

Glucagon-like peptide-1

HDL

High-density lipoprotein

HF

High fat

HRT

Hormone replacement therapy

IOM

Institute of Medicine

LDL

Low-density lipoprotein

LF

Low fat

NF- κB

Nuclear factor-kappa B

NMR

Nuclear magnetic resonance

NPY

Neuropeptide Y

OVX (OV)

Ovariectomized

PYY

Peptide YY

RER

Respiratory exchange ratio

RS

Resistant starch
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RQ

Respiratory quotient

SCFA

Short-chain fatty acid

SH

Sham operation

WAT

White adipose tissue
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APPENDIX C:
DEFINITIONS
Body Mass Index (BMI)

mass (kg)/height2 (m2)

Cecum

the beginning part of the large intestine that receives waste
material from the small intestine

Glucagon-like Peptide-1 (GLP-1)

gastrointestinal peptide and hormone that acts in inhibiting
food intake

Obesity

having a BMI of ≥30

Overweight

having a BMI of 25-29.9

Peptide YY (PYY)

gastrointestinal peptide and hormone known for its
anorectic properties

Respiratory Exchange Ratio (RER) ratio between CO2/%O2 used to indicate which fuel is
being oxidized for energy production in the body
Resistant starch (RS)

a type of starch that is resistant to the effects of digestive
enzymes and is not digested in the small intestine, but
fermented by microflora in the large intestine

Respiratory Quotient (RQ)

an indicator of which fuel (carbohydrate or fat) is being
metabolized to supply the body with energy at the cellular
level

Short-Chain Fatty Acids (SCFA)

end-product produced by fermentation of resistant starch in the
large intestine
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